References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Case<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet1975; 1: 72&#150;73<!-- HIGHWIRE ID="17:10:1840:1" --><A HREF="/cgi/external_ref?access_num=A1975V255000007&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=46024&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Anderson MJ, Jones SE, Fisher-Hoch SP <I>et al</I>. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet1983; 1: 1378<!-- HIGHWIRE ID="17:10:1840:2" --><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Taillan B, Heudier P, Ferrari E, Garnier G, Fuzibet JG, Dujardin P. Pure red-cell aplasia due to parvovirus B19 infection in a patient with AIDS-related complex. Ann Med1992; 24: 137<!-- HIGHWIRE ID="17:10:1840:3" --><A HREF="/cgi/external_ref?access_num=A1992HT20200013&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1610541&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Fisher D, Spencer D, Iland H, Brammah S, Cossart Y. Red cell aplasia caused by human parvovirus B19 in acute leukaemia. Aust N Z J Med1992; 22: 303&#150;304<!-- HIGHWIRE ID="17:10:1840:4" --><A HREF="/cgi/external_ref?access_num=A1992JB30600014&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1308098&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Kamper AM, Malbrain M, Zachee P, Chew SL. Parvovirus infection causing red cell aplasia and leukopenia in rheumatoid arthritis. Clin Rheumatol1994; 13: 129&#150;131<!-- HIGHWIRE ID="17:10:1840:5" --><A HREF="/cgi/external_ref?access_num=A1994NB61600023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8187436&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Bertoni E, Rosati A, Zanazzi M <I>et al</I>. Severe aplastic anaemia due to B19 parvovirus infection in renal transplant recipient. Nephrol Dial Transplant1995; 10: 1462&#150;1463<!-- HIGHWIRE ID="17:10:1840:6" --><A HREF="/cgi/external_ref?access_num=A1995RR98000039&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8538947&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Toda F, Toma H. Discontinuation of immunosuppressive antimetabolite for parvovirus B19-associated anemia in kidney transplant patients. Transplant Proc2000; 32: 1967&#150;1970<!-- HIGHWIRE ID="17:10:1840:7" --><A HREF="/cgi/external_ref?access_num=000166001400240&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11120023&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Sturm I, Watschinger B, Geissler K <I>et al</I>. Chronic parvovirus B19 infection-associated pure red cell anaemia in a kidney recipient. Nephrol Dial Transplant1996; 11: 1367&#150;1370<!-- HIGHWIRE ID="17:10:1840:8" --><A HREF="/cgi/external_ref?access_num=A1996UZ33600039&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8672044&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Shan YS, Lee PC, Wang JR, Teal HP, Sung CM, Jin YT. Fibrosing cholestatic hepatitis possibly related to persistent parvovirus B19 infection in a renal transplant recipient Nephrol Dial Transplant2001; 16: 2420&#150;2422<!-- HIGHWIRE ID="17:10:1840:9" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=ndt&resid=16/12/2420" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Lui SL, Luk WK, Cheung CY, Chan TM, Lai KN, Pelris JS. Nosocomlal outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation2001; 71: 59&#150;64<!-- HIGHWIRE ID="17:10:1840:10" --><A HREF="/cgi/external_ref?access_num=000166637500010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11211196&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> So BJ, Chae KM, Lee KK, Lee YJ, Jeong BH. Pure red cell aplasia due to parvovirus B19 infection in a renal transplant patient; a case report. Transplant proc2000; 32: 1954&#150;1958<!-- HIGHWIRE ID="17:10:1840:11" --><A HREF="/cgi/external_ref?access_num=000166001400234&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11120017&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Lee PC, Hung CJ, Lel HY, Chan TT, Wang JR, Jan MS. Parvovirus B19-related acute hepatitis in an Immunosuppressed kidney transplant. Nephrol Dial Transplant2000; 15: 1486&#150;1488<!-- HIGHWIRE ID="17:10:1840:12" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=ndt&resid=15/9/1486" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Pamidi S, Friedman K, Kampalath B, Eshoa C, Hariharan S. Human parvovirus B19 Infection presenting as persistent anemia in renal transplant recipients. Transplantation2000; 69: 2668&#150;2669<!-- HIGHWIRE ID="17:10:1840:13" --><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Moudgil A, Shidban H, Nast CC <I>et al.</I> Parvovirus B19 infection-related complications in renal transplant recipients: treatment with Intravenous immunoglobulin. Transplantation1987; 64: 1847&#150;1850<!-- HIGHWIRE ID="17:10:1840:14" --><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Ahsan N, Holman MJ, Gocke CD, Groff JA, Yang HC. Pure red cell aplasia due to parvovirus B19 Infection in solid organ transplantation. Clin Transplant1997; 11: 265&#150;270<!-- HIGHWIRE ID="17:10:1840:15" --><A HREF="/cgi/external_ref?access_num=A1997XQ57700004&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9267713&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Bertonl E, Rosati A, Zanazzi M, Azzi A, Zakrewska K, Guidl S, Salvadori M. Unusual incidence of aplastic anaemia due to B-19 parvovirus infection in renal transplant recipients. Transplant Proc1997; 29: 818&#150;819<!-- HIGHWIRE ID="17:10:1840:16" --><A HREF="/cgi/external_ref?access_num=A1997WM12700352&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9123540&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17> Uemura N, Ozawa K, Tani K <I>et al.</I> Pure red cell aplasia caused by parvovirus B19 Infection in a renal transplant recipient. Eur J Haematol1995; 54: 668&#150;69<!-- HIGHWIRE ID="17:10:1840:17" --><!-- /HIGHWIRE --></OL>

<FONT SIZE=-1>Received for publication: 20. 4.02</FONT><BR> 

<FONT SIZE=-1>Accepted in revised form: 11. 6.02
Several reports have related parvovirus infection and necrotizing<SUP> </SUP>vasculitides (Table 1<A HREF="#T1"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>) [<A HREF="#R2">2</A>&#150;<A HREF="#R9">9</A>]. In four cases it was associated<SUP> </SUP>with Wegener's granulomatosis, in eight with polyarteritis nodosa<SUP> </SUP>and in one with temporal arteritis. In none of these cases did<SUP> </SUP>an immunocompromising disease exist. Parvovirus has been reported<SUP> </SUP>to persist in immune-competent hosts [<A HREF="#R13">13</A>]. Most of the patients<SUP> </SUP>reported survived the infection with little or no sequelae [<A HREF="#R3">3</A>&#150;<A HREF="#R8">8</A>].<SUP> </SUP>Only two cases, the present one and a previously reported case<SUP> </SUP>of PAN, have died [<A HREF="#R9">9</A>]. Although in most reported cases the treatment<SUP> </SUP>consisted of immunosuppressive therapy and IVIG, two reports<SUP> </SUP>noted clinical recovery only after IVIG therapy [<A HREF="#R6">6</A>]. In one<SUP> </SUP>case the parvovirus infection was diagnosed early, hence IVIG<SUP> </SUP>was the only therapy given [<A HREF="#R8">8</A>]. In the other case, the resolution<SUP> </SUP>of symptoms occurred only after IVIG had been added to the immunosuppressive<SUP> </SUP>therapy [<A HREF="#R6">6</A>]. It is thus suggested that clinical recovery might<SUP> </SUP>coincide with the clearance of viraemia. The development of<SUP> </SUP>autoimmune phenomena during parvovirus infection is probably<SUP> </SUP>related to a poor host response and might be associated with<SUP> </SUP>immune complex formation. Such a mechanism has been suggested<SUP> </SUP>as the cause of vasculitides in chronic hepatitis B infections<SUP> </SUP>[<A HREF="#R14">14</A>]. This hypothesis is supported by cases in which the resolution<SUP> </SUP>of symptoms occurred only after IVIG treatment. In only one<SUP> </SUP>of the cases reported previously was the vasculitis associated<SUP> </SUP>with myelosuppression (case 3 in [<A HREF="#R6">6</A>]). Although red cell aplasia<SUP> </SUP>is the classical presentation of the effect of parvovirus on<SUP> </SUP>bone marrow, leucopenia and myelosuppression have been associated<SUP> </SUP>with chronic parvovirus infection [<A HREF="#R1">1</A>, <A HREF="#R15">15</A>]. In the case reported<SUP> </SUP>here, the serological findings compatible with recent infection<SUP> </SUP>with parvovirus, accompanied by myelosuppression and vasculitis,<SUP> </SUP>is strongly suggestive of a cause-and-effect relationship. The<SUP> </SUP>serology tests for parvovirus have low sensitivity but high<SUP> </SUP>specificity for infection [<A HREF="#R16">16</A>]. We believe that the clinical<SUP> </SUP>presentation of myelosuppression and vasculitis were caused<SUP> </SUP>by persistent parvovirus infection. Although the patient was<SUP> </SUP>not immunocompromised, his poor immunological response to the<SUP> </SUP>virus might have been related to his age or to underlying MDS<SUP> </SUP>that was not diagnosed earlier. This is the second case of vasculitis<SUP> </SUP>and concurrent myelosuppression due to parvovirus B19 infection.<SUP> </SUP>This case adds to the increasing evidence for a possible association<SUP> </SUP>of vasculitis with parvovirus infection
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Patients and methods<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997;8:314&#150;22.<!-- HIGHWIRE ID="42:5:660:1" --><A HREF="/cgi/external_ref?access_num=A1997WJ55300018&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9048352&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Hoffman GS, Kerr GS, Leavitt RY <I>et al</I>. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488&#150;98.<!-- HIGHWIRE ID="42:5:660:2" --><A HREF="/cgi/external_ref?access_num=A1992HJ59800010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1739240&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Guillevin L, Durand-Gasselin B, Cevallos R <I>et al</I>. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421&#150;30.<!-- HIGHWIRE ID="42:5:660:3" --><A HREF="/cgi/external_ref?access_num=10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000079123700005&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10088763&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg&#150;Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26&#150;37.<!-- HIGHWIRE ID="42:5:660:4" --><A HREF="/cgi/external_ref?access_num=10.1097/00005792-199901000-00003&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000078361600003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9990352&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Russell KA, Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. Rheum Dis Clin North Am 2001;27:815&#150;32,vii.<!-- HIGHWIRE ID="42:5:660:5" --><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Murphy FA, Fauquet CM, Bishop DHL <I>et al</I>. Virus taxonomy&#151;classification and nomenclature of viruses: sixth report of the International Committee on Taxonomy of Viruses. Vienna: Springer-Verlag,1995.<!-- HIGHWIRE ID="42:5:660:6" --><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Brown KE. Human parvovirus B19 epidemiology and clinical manifestations. In: Young NS, ed. Human parvovirus B19. New York: Karger,1997:42&#150;55.<!-- HIGHWIRE ID="42:5:660:7" --><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Nguyen QT, Sifer C, Schneider V <I>et al</I>. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999;37:2483&#150;7.<!-- HIGHWIRE ID="42:5:660:8" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcm&resid=37/8/2483" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Nguyen QT, Sifer C, Schneider V, Bernaudin F, Auguste V, Garbarg-Chenon A. Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia [letter]. Lancet 1998;352:1524.<!-- HIGHWIRE ID="42:5:660:9" --><A HREF="/cgi/external_ref?access_num=10.1016/S0140-6736(98)22021-6&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000076862300018&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9820308&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Servant A, Laperche S, Lallemand F <I>et al</I>. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002;76:9124&#150;34.<!-- HIGHWIRE ID="42:5:660:10" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=76/18/9124" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Finkel TH, Torok TJ, Ferguson PJ <I>et al</I>. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994;343:1255&#150;8.<!-- HIGHWIRE ID="42:5:660:11" --><A HREF="/cgi/external_ref?access_num=A1994NM14400010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7910276&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Corman LC, Staud R. Association of Wegener's granulomatosis with parvovirus B19 infection: comment on the concise communication by Nikkari <I>et al</I>. Arthritis Rheum 1995;38:1174&#150;5.<!-- HIGHWIRE ID="42:5:660:12" --><A HREF="/cgi/external_ref?access_num=A1995RP62000025&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7639819&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Nikkari S, Mertsola J, Korvenranta H, Vainionp&auml;&auml; R, Toivanen P. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1994;37:1707&#150;8.<!-- HIGHWIRE ID="42:5:660:13" --><A HREF="/cgi/external_ref?access_num=A1994PQ61500022&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7980681&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Gaches F, Loustaud V, Vidal E <I>et al</I>. Periarteritis nodosa and parvovirus B19 infection [French]. Rev M&eacute;d Intern 1993;14:323&#150;5.<!-- HIGHWIRE ID="42:5:660:14" --><A HREF="/cgi/external_ref?access_num=A1993LG92900011&link_type=ISI" >[ISI]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Leruez-Ville M, Lauge A, Morinet F, Guillevin L, Deny P. Polyarteritis nodosa and parvovirus B19 [letter]. Lancet 1994;344:263&#150;4.<!-- HIGHWIRE ID="42:5:660:15" --><A HREF="/cgi/external_ref?access_num=7913176&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Nigro G, Zerbini M, Krzysztofiak A <I>et al</I>. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet 1994;343:1260&#150;1.<!-- HIGHWIRE ID="42:5:660:16" --><A HREF="/cgi/external_ref?access_num=A1994NM14400012&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7910278&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17> Staud R, Corman LC. Association of parvovirus B19 infection with giant cell arteritis. Clin Infect Dis 1996;22:1123.<!-- HIGHWIRE ID="42:5:660:17" --><A HREF="/cgi/external_ref?access_num=A1996UQ79400051&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8783735&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R18"><!-- null --></A>
<LI VALUE=18> Chou TN, Hsu TC, Chen RM, Lin LI, Tsay GJ. Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL). Lupus 2000;9:551&#150;4.<!-- HIGHWIRE ID="42:5:660:18" --><A HREF="/cgi/external_ref?access_num=000089253600014&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11035424&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R19"><!-- null --></A>
<LI VALUE=19> Leavitt RY, Fauci AS, Bloch DA <I>et al</I>. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101&#150;7.<!-- HIGHWIRE ID="42:5:660:19" --><A HREF="/cgi/external_ref?access_num=A1990DV71700006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2202308&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R20"><!-- null --></A>
<LI VALUE=20> Masi AT, Hunder GG, Lie JT <I>et al</I>. The American College of Rheumatology 1990 criteria for the classification of Churg&#150;Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094&#150;100.<!-- HIGHWIRE ID="42:5:660:20" --><A HREF="/cgi/external_ref?access_num=A1990DV71700005&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2202307&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R21"><!-- null --></A>
<LI VALUE=21> Jennette JC, Falk RJ, Andrassy K <I>et al</I>. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187&#150;92.<!-- HIGHWIRE ID="42:5:660:21" --><A HREF="/cgi/external_ref?access_num=A1994MW50900005&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8129773&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R22"><!-- null --></A>
<LI VALUE=22> Bruu AL, Nordbo SA. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19. J Clin Microbiol 1995;33:1363&#150;5.<!-- HIGHWIRE ID="42:5:660:22" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcm&resid=33/5/1363" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R23"><!-- null --></A>
<LI VALUE=23> Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999;57:179&#150;85.<!-- HIGHWIRE ID="42:5:660:23" --><A HREF="/cgi/external_ref?access_num=10.1002/(SICI)1096-9071(199902)57:2<179::AID-JMV16>3.0.CO;2-T&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000077873100016&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9892405&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R24"><!-- null --></A>
<LI VALUE=24> Bengtsson A, Widell A, Elmstahl S, Sturfelt G. No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis 2000;59:64&#150;6.<!-- HIGHWIRE ID="42:5:660:24" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annrheumdis&resid=59/1/64" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R25"><!-- null --></A>
<LI VALUE=25> Heegaard ED, Qvortrup K, Christensen J. Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: serologic cross-reactivity with erythrovirus B19. J Med Virol 2002;66:246&#150;52.<!-- HIGHWIRE ID="42:5:660:25" --><A HREF="/cgi/external_ref?access_num=10.1002/jmv.2137&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000172929900015&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11782935&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R26"><!-- null --></A>
<LI VALUE=26> Elling H, Olsson AT, Elling P. Human parvovirus and giant cell arteritis: a selective arteritic impact? Clin Exp Rheumatol 2000;18(4 Suppl. 20):S12&#150;4.<!-- HIGHWIRE ID="42:5:660:26" --><A HREF="/cgi/external_ref?access_num=10948750&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R27"><!-- null --></A>
<LI VALUE=27> Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999;42:1255&#150;8.<!-- HIGHWIRE ID="42:5:660:27" --><A HREF="/cgi/external_ref?access_num=10.1002/1529-0131(199906)42:6<1255::AID-ANR23>3.0.CO;2-P&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000080786000023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10366119&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R28"><!-- null --></A>
<LI VALUE=28> Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B19, <I>Chlamydia pneumoniae</I> or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology 2002;41:445&#150;9.<!-- HIGHWIRE ID="42:5:660:28" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=rheumatology&resid=41/4/445" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R29"><!-- null --></A>
<LI VALUE=29> Kiraz S, Ozturk MA, Ertenli I, Calguneri M. Parvovirus B19 infection in Behcet's disease. Ann Rheum Dis 2001;60:814&#150;5.<!-- HIGHWIRE ID="42:5:660:29" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=annrheumdis&resid=60/8/814" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R30"><!-- null --></A>
<LI VALUE=30> Nikkari S, Vainionp&auml;&auml; R, Toivanen P <I>et al</I>. Association of Wegener's granulomatosis with parvovirus B19 infection: comment on the concise communication by Nikkari <I>et al</I>. Reply. Arthritis Rheum 1995;38:1174&#150;5.<!-- HIGHWIRE ID="42:5:660:30" --><A HREF="/cgi/external_ref?access_num=A1995RP62000025&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7639819&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R31"><!-- null --></A>
<LI VALUE=31> Choi HK, Lamprecht P, Niles JL, Gross WL, Merkel PA. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000;43:226&#150;31.<!-- HIGHWIRE ID="42:5:660:31" --><A HREF="/cgi/external_ref?access_num=10.1002/1529-0131(200001)43:1<226::AID-ANR27>3.0.CO;2-Q&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000084782700027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10643719&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></OL>

Submitted  31 July 2002; 

Accepted 22 November 2002
Submitted  20 October 1999; 
revised version accepted 15 February 2000. 

<A NAME="BIBL"><!-- null --></A>
<BR CLEAR=right><TABLE WIDTH=100% BGCOLOR=e1e1e1 CELLPADDING=0 CELLSPACING=0>
 <TR><TD ALIGN=left VALIGN=middle WIDTH=5% BGCOLOR=ffffff><IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT=" "
SRC="/icons/toc/rarrow.gif"></TD>
 <TH ALIGN=left VALIGN=middle WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Note added in proof<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Brown KE. Human parvovirus B19 epidemiology and clinical manifestations. In: Anderson LJ, Young NS, eds. Human parvovirus B19. Monographs in virology, Vol. 20. New York: Karger, 1997;42&#150;60.<!-- HIGHWIRE ID="39:8:903:1" --><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K <I>et al</I>. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA1998;95:8227&#150;32.<!-- HIGHWIRE ID="39:8:903:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=95/14/8227" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Kerr JR, Cartron JP, Curran MD <I>et al</I>. A study of the role of parvovirus B19 in rheumatoid arthritis. Br J Rheumatol1995;34:809&#150;13.<!-- HIGHWIRE ID="39:8:903:3" --><A HREF="/cgi/external_ref?access_num=A1995RZ77200004&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7582718&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Astell CR, Weixing L, Brunstein J, Amand JS. The genome of B19 parvovirus. In: Anderson LJ, Young NS, eds. Human parvovirus B19. Monographs in virology, Vol. 20. New York: Karger, 1997;16&#150;41.<!-- HIGHWIRE ID="39:8:903:4" --><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O <I>et al</I>. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol1996;70:8485&#150;91.<!-- HIGHWIRE ID="39:8:903:5" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=70/12/8485" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Von Poblotzki A, Gigler A, Lang B, Wolf H, Modrow S. Antibodies to parvovirus B19 NS1 protein in infected individuals. J Gen Virol1995;76:519&#150;27.<!-- HIGHWIRE ID="39:8:903:6" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=vir&resid=76/3/519" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Von Poblotzki A, Hemauer A, Gigler A <I>et al</I>. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implication for pathogenesis. J Infect Dis1995;172:1356&#150;9.<!-- HIGHWIRE ID="39:8:903:7" --><A HREF="/cgi/external_ref?access_num=A1995TA55200027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7594677&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Searle K, Schalasta G, Enders G. Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful. J Med Virol1998;56:192&#150;8.<!-- HIGHWIRE ID="39:8:903:8" --><A HREF="/cgi/external_ref?access_num=000076224500003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9783684&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Venturoli S, Gallinella G, Manaresi E, Gentilomi G, Musiani M, Zerbini M. IgG response to the immunoreactive region of parvovirus B19 nonstructural protein by immunoblot assay with a recombinant antigen. J Infect Dis1998;178:1826&#150;9.<!-- HIGHWIRE ID="39:8:903:9" --><A HREF="/cgi/external_ref?access_num=000077466700043&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9815244&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Jones LP, Erdman DD, Anderson LJ. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis1999;180:500&#150;4.<!-- HIGHWIRE ID="39:8:903:10" --><A HREF="/cgi/external_ref?access_num=000081767000034&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10395869&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Kerr JR, Curran MD, Moore JE, Murphy PG. Parvovirus B19 infection&#151;persistence and genetic variation. Scand J Infect Dis1995;27:551&#150;7.<!-- HIGHWIRE ID="39:8:903:11" --><A HREF="/cgi/external_ref?access_num=A1995TZ30400003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8685632&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Kerr JR, Coyle PV, DeLeys RJ <I>et al</I>. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection. J Med Virol1996;48:68&#150;75.<!-- HIGHWIRE ID="39:8:903:12" --><A HREF="/cgi/external_ref?access_num=A1996TU84400011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8825713&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Hicks KE, Cubel RC, Cohen BJ, Clewley JP. Sequence analysis of a parvovirus B19 isolate and baculovirus expression of the non-structural protein. Arch Virol1996;141:1319&#150;27.<!-- HIGHWIRE ID="39:8:903:13" --><A HREF="/cgi/external_ref?access_num=A1996VB38800012&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8774690&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Gigler A, Dorsch S, Hemauer A <I>et al</I>. Generation of neutralising human monoclonal antibodies against parvovirus B19 proteins. J Virol1999;73:1974&#150;9.<!-- HIGHWIRE ID="39:8:903:14" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=73/3/1974" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Cotmore SF, Tattersall P. A genome-linked copy of the NS1 polypeptide is located on the outside of infectious parvovirus particles. J Virol1989;63:3902&#150;11.<!-- HIGHWIRE ID="39:8:903:15" --><A HREF="/cgi/external_ref?access_num=A1989AK28400042&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2527311&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Hemauer A, Gigler A, Searle K <I>et al</I>. Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women. J Med Virol2000;60:48&#150;55.<!-- HIGHWIRE ID="39:8:903:16" --><A HREF="/cgi/external_ref?access_num=000084062000009&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10568763&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></OL>

<HR>&nbsp;<BR>







<A NAME="SEC4"><!-- null --></A>
<BR CLEAR=right><TABLE WIDTH=100% BGCOLOR=e1e1e1 CELLPADDING=0 CELLSPACING=0>
 <TR><TD ALIGN=left VALIGN=middle WIDTH=5% BGCOLOR=ffffff><IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT=" "
SRC="/icons/toc/rarrow.gif"></TD>
 <TH ALIGN=left VALIGN=middle WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;
Note added in proof
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">References<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Note added in proof</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Further evidence for the correlation of NS1 antibodies with<SUP> </SUP>severe courses of B19 infection is provided by Hemauer <I>et al</I>.<SUP> </SUP>[<A HREF="#R16">16
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Case report<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Patients and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results and discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 2000;59:672&#150;83.<!-- HIGHWIRE ID="42:2:349:1" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=annrheumdis&resid=59/9/672" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Chevrel G, Calvet A, Belin V, Miossec P. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology 2000;39:1037&#150;9.<!-- HIGHWIRE ID="42:2:349:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=rheumatology&resid=39/9/1037" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344&#150;7.<!-- HIGHWIRE ID="42:2:349:3" --><A HREF="/cgi/external_ref?access_num=A1975V510400006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1090839&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986;58:921&#150;36.<!-- HIGHWIRE ID="42:2:349:4" --><A HREF="/cgi/external_ref?access_num=A1986C410300026&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=3701931&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Torok TJ, Wang QY, Gary GW, Jr., Yang CF, Finch TM, Anderson LJ. Prenatal diagnosis of intrauterine infection with parvovirus B19 by the polymerase chain reaction technique. Clin Infect Dis 1992;14:149&#150;55.<!-- HIGHWIRE ID="42:2:349:5" --><A HREF="/cgi/external_ref?access_num=A1992HD51700023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1571420&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992;127:5&#150;24.<!-- HIGHWIRE ID="42:2:349:6" --><A HREF="/cgi/external_ref?access_num=A1992JD81800001&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1387110&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Soderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063&#150;5.<!-- HIGHWIRE ID="42:2:349:7" --><A HREF="/cgi/external_ref?access_num=10.1016/S0140-6736(96)09110-6&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=A1997WU00200011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9107245&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Takahashi Y, Murai C, Shibata S <I>et al</I>. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:8227&#150;32.<!-- HIGHWIRE ID="42:2:349:8" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=95/14/8227" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Bousvaros A, Sundel R, Thorne GM <I>et al</I>. Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol 1998;26:365&#150;9.<!-- HIGHWIRE ID="42:2:349:9" --><A HREF="/cgi/external_ref?access_num=10.1002/(SICI)1099-0496(199811)26:5<365::AID-PPUL11>3.0.CO;2-4&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000077362400011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9859908&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis 1995;21:430&#150;2.<!-- HIGHWIRE ID="42:2:349:10" --><A HREF="/cgi/external_ref?access_num=A1995RM81700027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8562756&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Kerr JR, Barrett AM, Curran MD, Behan WMH, Middleton D, Behan PO. Parvovirus B19 and chronic fatigue syndrome. J Chronic Fatigue Syndr 1997;3:101&#150;7.<!-- HIGHWIRE ID="42:2:349:11" --><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Finkel TH, Torok TJ, Ferguson PJ <I>et al</I>. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994;343:1255&#150;8.<!-- HIGHWIRE ID="42:2:349:12" --><A HREF="/cgi/external_ref?access_num=A1994NM14400010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7910276&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001;344:1481&#150;2.<!-- HIGHWIRE ID="42:2:349:13" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=344/19/1481" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Kalish RA, Knopf AN, Gary GW, Canoso JJ. Lupus-like presentation of human parvovirus B19 infection. J Rheumatol 1992;19:169&#150;71.<!-- HIGHWIRE ID="42:2:349:14" --><A HREF="/cgi/external_ref?access_num=A1992HF28900034&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1556683&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Miki NP, Chantler JK. Non-permissiveness of synovial membrane cells to human parvovirus B19 <I>in vitro</I>. J Gen Virol 1992;73:1559&#150;62.<!-- HIGHWIRE ID="42:2:349:15" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=vir&resid=73/6/1559" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Ray NB, Nieva DR, Seftor EA, Khalkhali-Ellis Z, Naides SJ. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum 2001;44:1582&#150;6.<!-- HIGHWIRE ID="42:2:349:16" --><A HREF="/cgi/external_ref?access_num=10.1002/1529-0131(200107)44:7<1582::AID-ART281>3.0.CO;2-E&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000172491000015&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11465709&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17> Moffatt S, Tanaka N, Tada K <I>et al</I>. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996;70:8485&#150;91.<!-- HIGHWIRE ID="42:2:349:17" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=70/12/8485" >[Abstract]</A><!-- /HIGHWIRE --></OL>

Submitted  14 December 2001; 

Accepted  2 August 2002
Garcia-Tapia AM, Fernandez-Gutierrez del Alamo C, Giron JA<I>et al</I>. Spectrum of parvovirus B19 infection: Analysis of an outbreak of 43 cases in Cadiz, Spain. Clin Infect Dis 1995;21:1424&#150;30.<!-- HIGHWIRE ID="41:10:1210:1" --><A HREF="/cgi/external_ref?access_num=A1995TL79500013&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8749627&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Nikkari S, Mertsola J, Kovernata H, Vainiopaa R, Toinavanen P. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1994;37:1707&#150;8.<!-- HIGHWIRE ID="41:10:1210:2" --><A HREF="/cgi/external_ref?access_num=A1994PQ61500022&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7980681&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Corman LC, Staud R. Association of Wegener's granulomatosis with parvovirus B19 infection [comment]. Arthritis Rheum 1995;38:1174&#150;5.<!-- HIGHWIRE ID="41:10:1210:3" --><A HREF="/cgi/external_ref?access_num=A1995RP62000025&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7639819&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Corman LC, Dolson DJ. Parvovirus B19 and necrotizing vasculitis [abstract]. Arthritis Rheum 1992;35(Suppl. 9):S165.<!-- HIGHWIRE ID="41:10:1210:4" --><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Corman LC, Dolson DJ. Polyarteritis nodosa and parvovirus B19 infection. Lancet 1992;339:491.<!-- HIGHWIRE ID="41:10:1210:5" --><A HREF="/cgi/external_ref?access_num=A1992HE93200029&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1346840&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Finkel TH, Torok TJ, Ferguson PJ <I>et al</I>. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or etiological agent? Lancet 1994;343:1255&#150;8.<!-- HIGHWIRE ID="41:10:1210:6" --><A HREF="/cgi/external_ref?access_num=A1994NM14400010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7910276&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Zulian F, Costantini C, Montesco MC, Shiavon F, Zacchello F. Successful treatment of gangrene in systemic necrotizing vasculitis with Iloprost. Br J Rheumatol 1998;37:228&#150;30.<!-- HIGHWIRE ID="41:10:1210:7" --><A HREF="/cgi/external_ref?access_num=000072732800020&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9569082&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001;344:1481&#150;2.<!-- HIGHWIRE ID="41:10:1210:8" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=344/19/1481" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Gaches F, Loustaud V, Vidal E <I>et al</I>. P&eacute;riart&eacute;rite noueuse et infection par le parvovirus B19. Rev Med Intern 1993;14:323&#150;5.<!-- HIGHWIRE ID="41:10:1210:9" --><A HREF="/cgi/external_ref?access_num=A1993LG92900011&link_type=ISI" >[ISI]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B 19 in England and Wales. J Med Microbiol 1988;25:151&#150;3.<!-- HIGHWIRE ID="41:10:1210:10" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=medmicro&resid=25/2/151" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Pirayesh A, Verbunt RJ, Kluin PM <I>et al</I>. Myelodysplastic syndrome with vasculitic manifestation. J Intern Med 1997;242:425&#150;31.<!-- HIGHWIRE ID="41:10:1210:11" --><A HREF="/cgi/external_ref?access_num=000071006900014&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9408074&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Brickner LA, Scannell KA. Medium vessel PAN-type vasculitis associated with myelodysplastic syndrome. Clin Exp Rheumatol 1997;15:221&#150;2.<!-- HIGHWIRE ID="41:10:1210:12" --><A HREF="/cgi/external_ref?access_num=A1997WX89500018&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9196879&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Tyndall A, Jelk W, Hirsch HH. Parvovirus B19 and erosive polyarthritis. Lancet 1993;19:457.<!-- HIGHWIRE ID="41:10:1210:13" --><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg&#150;Strauss syndrome. Lupus 1998;7:238&#150;58.<!-- HIGHWIRE ID="41:10:1210:14" --><A HREF="/cgi/external_ref?access_num=000074133900006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9643314&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Habib G, Cohen L. Many faces of parvovirus. Harefuah 1999;136:936&#150;7.<!-- HIGHWIRE ID="41:10:1210:15" --><A HREF="/cgi/external_ref?access_num=10955152&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Anderson LJ, Tsou C, Parker RA <I>et al</I>. Detection of antibodies and antigen of human parvovirus B19 by enzyme linked immunosorbent assay. J Clin Microbiol 1986;24:522&#150;6.<!-- HIGHWIRE ID="41:10:1210:16" --><A HREF="/cgi/external_ref?access_num=A1986E113700005&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=3021807&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></OL>



Accepted 16 April 2002
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Case report<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Plotz PH. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995;122:715&#150;24.<!-- HIGHWIRE ID="39:9:1037:1" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annintmed&resid=122/9/715" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Takahashi Y, Murai C, Shibata S <I>et al</I>. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA1998;95:8227&#150;32.<!-- HIGHWIRE ID="39:9:1037:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=95/14/8227" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organisation of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol1986;58:921&#150;36.<!-- HIGHWIRE ID="39:9:1037:3" --><A HREF="/cgi/external_ref?access_num=A1986C410300026&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=3701931&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> T&ouml;r&ouml;k TJ, Wang QY, Gary GW, Yang CF, Finch TM, Anderson LJ. Prenatal diagnosis of intrauterine infection with parvovirus B19 by the polymerase chain reaction technique. Clin Infect Dis1992;14:149&#150;55.<!-- HIGHWIRE ID="39:9:1037:4" --><A HREF="/cgi/external_ref?access_num=A1992HD51700023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1571420&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Leff RL, Love LA, Miller FW <I>et al</I>. Viruses in idiopathic inflammatory myopathies/ absence of candidate viral genomes in muscle. Lancet1992;339:1192&#150;5.<!-- HIGHWIRE ID="39:9:1037:5" --><A HREF="/cgi/external_ref?access_num=A1992HU68400004&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1349938&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Kerr JR. Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis1996;15:10&#150;29.<!-- HIGHWIRE ID="39:9:1037:6" --><A HREF="/cgi/external_ref?access_num=A1996TW30500003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8641299&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum1997;40:103&#150;8.<!-- HIGHWIRE ID="39:9:1037:7" --><A HREF="/cgi/external_ref?access_num=A1997WD15200014&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9008606&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Cassinotti P, Siegl G, Michel BA, Br&uuml;hlmann P. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J Med Virol1998;56:199&#150;204.<!-- HIGHWIRE ID="39:9:1037:8" --><A HREF="/cgi/external_ref?access_num=000076224500004&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9783685&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Kalish RA, Knopf AN, Gary GW, Canoso JJ. Lupus-like presentation of human parvovirus B19 infection. J Rheumatol1992;19:169&#150;71.<!-- HIGHWIRE ID="39:9:1037:9" --><A HREF="/cgi/external_ref?access_num=A1992HF28900034&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1556683&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis1995;21:430&#150;32.<!-- HIGHWIRE ID="39:9:1037:10" --><A HREF="/cgi/external_ref?access_num=A1995RM81700027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8562756&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Bousvaros A, Sundel R, Thorne GM <I>et al</I>. Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol1998;26:365&#150;9.<!-- HIGHWIRE ID="39:9:1037:11" --><A HREF="/cgi/external_ref?access_num=000077362400011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9859908&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> S&ouml;derlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet1997;349:1063&#150;65.<!-- HIGHWIRE ID="39:9:1037:12" --><A HREF="/cgi/external_ref?access_num=A1997WU00200011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9107245&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol1997;53:229&#150;32.<!-- HIGHWIRE ID="39:9:1037:13" --><A HREF="/cgi/external_ref?access_num=A1997YE75500008&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9365887&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Nikkari S, Vuorinen T, Kotilainen P, Lammintausta K. Presence of parvovirus B19 DNA in the skin of healthy individuals [abstract]. Arthritis Rheum1999;42:S338.<!-- HIGHWIRE ID="39:9:1037:14" --><A HREF="/cgi/external_ref?access_num=000082936301686&link_type=ISI" >[ISI]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Von Poblotski A, Hemauer A, Gigler A <I>et al</I>. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis1995;172:1356&#150;9.<!-- HIGHWIRE ID="39:9:1037:15" --><A HREF="/cgi/external_ref?access_num=A1995TA55200027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7594677&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Sol N, Le Junter J, Vassias I <I>et al</I>. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol1999;73:8762&#150;70.<!-- HIGHWIRE ID="39:9:1037:16" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=73/10/8762" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --></OL>

Submitted   7 July 1999; 

Accepted 24 February 2000
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Case<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1>
 Chisari FV, Filippi P, Buras J <I>et al</I>. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA1987; 84: 6909&#150;6913<!-- HIGHWIRE ID="16:12:2420:1" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=84/19/6909" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2>
 Lau YN, Bain VG, Davies SE <I>et al</I>. High level expression of hepatitis B virus (HBV) antigens in fibrosing cholestatic hepatitis. Evidence that HBV may be cytopathic in liver grafts. Gastroenterology1992; 102: 956&#150;962<!-- HIGHWIRE ID="16:12:2420:2" --><A HREF="/cgi/external_ref?access_num=A1992HF72100028&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1537531&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3>
 Mason AL, Wick M, White HM <I>et al</I>. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology1993; 105: 237&#150;244<!-- HIGHWIRE ID="16:12:2420:3" --><A HREF="/cgi/external_ref?access_num=A1993LJ98400030&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8514040&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4>
 Zylberberg H, Carnot F, Mawzer MF, Blancho G, Legendre C, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation1997; 63: 158&#150;160<!-- HIGHWIRE ID="16:12:2420:4" --><A HREF="/cgi/external_ref?access_num=A1997WD06600028&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9000679&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5>
 Brown KE, Young NS. Parvovirus B19 in human disease. Annu Rev Med1997; 48: 59&#150;67<!-- HIGHWIRE ID="16:12:2420:5" --><A HREF="/cgi/external_ref?access_num=A1997WH48600006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9046945&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6>
 Tsuda H. Liver dysfunction caused by parvovirus B19. Am J Gastroenterol1993; 88: 1463<!-- HIGHWIRE ID="16:12:2420:6" --><A HREF="/cgi/external_ref?access_num=A1993LW16600043&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8362857&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7>
 Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol1998; 93: 468&#150;470<!-- HIGHWIRE ID="16:12:2420:7" --><A HREF="/cgi/external_ref?access_num=000073194100047&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9517662&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8>
 Langnas AN, Markin RS, Cattral MS, Naides SJ. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology1995; 22: 1661&#150;1665<!-- HIGHWIRE ID="16:12:2420:8" --><A HREF="/cgi/external_ref?access_num=A1995TK47400007&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7489971&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9>
 Lee PC, Hung CJ, Lei HY, Chang TT, Wang JR, Jan MS. Parvovirus B19-related hepatitis in an immunosuppressed kidney transplant. Nephrol Dial Transplant2000; 15: 1486&#150;1488<!-- HIGHWIRE ID="16:12:2420:9" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=ndt&resid=15/9/1486" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10>
 Musiani M, Zerbini M, Gentilomi G <I>et al</I>. Persistent B19 parvovirus infections in haemophilic HIV-1 infected patients. J Med Virol1995; 46: 103&#150;108<!-- HIGHWIRE ID="16:12:2420:10" --><A HREF="/cgi/external_ref?access_num=A1995RA82800003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7636495&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11>
 Moudgil A, Shidban H, Nast CC <I>et al</I>. Parvovirus B19 infection-related complications in renal transplant recipients. Treatment with intravenous immunoglobulin. Transplantation1997; 64: 1847&#150;1850<!-- HIGHWIRE ID="16:12:2420:11" --><A HREF="/cgi/external_ref?access_num=000071404400037&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9422430&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12>
 Frichhofen N, Abkowitz JL, Sufford M <I>et al</I>. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus typeI (HIV-I): a treatable cause of anemia in AIDS. Ann Intern Med1990; 113: 926&#150;933<!-- HIGHWIRE ID="16:12:2420:12" --><A HREF="/cgi/external_ref?access_num=A1990EM29700006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2173460&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13>
 Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during Lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology1999; 30: 770&#150;774<!-- HIGHWIRE ID="16:12:2420:13" --><A HREF="/cgi/external_ref?access_num=000082259500023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10462384&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14>
 Brind AM, Bennett MK, Bassendine MF. Nucloside analogue therapy in fibrosing cholestatic hepatitis&#151;a case report in an HBsAg positive renal transplat recipient. Liver1998; 18: 134&#150;139<!-- HIGHWIRE ID="16:12:2420:14" --><A HREF="/cgi/external_ref?access_num=000073451500009&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9588773&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></OL>

<FONT SIZE=-1>Received for publication: 23.12.00</FONT><BR> 
Revision received 22. 5.01
Chevrel G, Calvet A, Belin V, Miossec P. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology2000;39:1037&#150;9.<!-- HIGHWIRE ID="41:7:833-a:1" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=rheumatology&resid=39/9/1037" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Kerr JR, Barrett AM, Curran MD, Behan WMH, Middleton D, Behan PO. Parvovirus B19 and chronic fatigue syndrome. Chronic Fatigue Syndrome1997;3:101&#150;7.<!-- HIGHWIRE ID="41:7:833-a:2" --><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organisation of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol1986;58:921&#150;36.<!-- HIGHWIRE ID="41:7:833-a:3" --><A HREF="/cgi/external_ref?access_num=A1986C410300026&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=3701931&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Blundell MC, Beard C, Astell CR. In vitro identification of a B19 parvovirus promoter. Virology1987;57:534&#150;8.<!-- HIGHWIRE ID="41:7:833-a:4" --><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Hokynar K, Brunstein J, Soderlund-Venermo M <I>et al.</I> Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. J Gen Virol2000;81:1017&#150;25.<!-- HIGHWIRE ID="41:7:833-a:5" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=vir&resid=81/4/1017" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Momoeda M Wong S, Kawase M, Young NS, Kajigaya S. A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol1994;68:8443&#150;6.<!-- HIGHWIRE ID="41:7:833-a:6" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=68/12/8443" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA2000;97:4862&#150;6.<!-- HIGHWIRE ID="41:7:833-a:7" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=97/9/4862" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> Kalish RA, Knopf AN, Gary GW, Canoso JJ. Lupus-like presentation of human parvovirus B19 infection. J Rheumatol1992;19:169&#150;71.<!-- HIGHWIRE ID="41:7:833-a:8" --><A HREF="/cgi/external_ref?access_num=A1992HF28900034&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1556683&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis1995;21:430&#150;2.<!-- HIGHWIRE ID="41:7:833-a:9" --><A HREF="/cgi/external_ref?access_num=A1995RM81700027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8562756&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Bousvaros A, Sundel R, Thorne GM <I>et al.</I> Parvovirus B19-associated interstitial lung disease, hepatitis and myositis. Pediatr Pulmonol1998;26:365&#150;9.<!-- HIGHWIRE ID="41:7:833-a:10" --><A HREF="/cgi/external_ref?access_num=000077362400011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9859908&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Crowson AN, Magro CM, Dawood MR. A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol2000;27:505&#150;15.<!-- HIGHWIRE ID="41:7:833-a:11" --><A HREF="/cgi/external_ref?access_num=000165181800004&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11100810&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Klouda PT, Corbin SA, Bradley BA, Cohen BJ, Woolf AD. HLA and acute arthritis following human parvovirus infection. Tissue Antigens1986;28:318&#150;9.<!-- HIGHWIRE ID="41:7:833-a:12" --><A HREF="/cgi/external_ref?access_num=A1986F399500009&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=3029894&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> Gendi NST, Gibson K, Wordsworth BP. Effect of HLA type and hypocomplementaemia on the expression of parvovirus arthritis: one year follow up of an outbreak. Ann Rheum Dis1996;55:63&#150;5.<!-- HIGHWIRE ID="41:7:833-a:13" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annrheumdis&resid=55/1/63" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Soriano ER, McHugh NJ. Overlap syndromes in adults and children. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology, edn 2. Oxford: Oxford University Press, 1999:1413&#150;32.<!-- HIGHWIRE ID="41:7:833-a:14" --><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> Targoff IN. Polymyositis and dermatomyositis. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology, edn 2. Oxford: Oxford University Press, 1999:1250&#150;86.<!-- HIGHWIRE ID="41:7:833-a:15" --><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Kerr JR, Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis2000;59:672&#150;83.<!-- HIGHWIRE ID="41:7:833-a:16" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=annrheumdis&resid=59/9/672" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17> Kerr JR, Barah F, Mattey DL <I>et al.</I> Serum tumour necrosis factor-<I><IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"></I> (TNF-<I><IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"></I>) and interferon-<I><IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"></I> (IFN-<I><IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"></I>) are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol2001;82:3011&#150;9.<!-- HIGHWIRE ID="41:7:833-a:17" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=vir&resid=82/12/3011" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R18"><!-- null --></A>
<LI VALUE=18> Reed JL, Kucukcetin B, Koenig S. Mechanisms of parvovirus B19 persistence in peripheral blood mononuclear cells. Infect Dis Rev2000;2:169.<!-- HIGHWIRE ID="41:7:833-a:18" --><!-- /HIGHWIRE --></OL>



Accepted 12 February 2002
Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Introduction<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Methods<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


Human parvovirus B19 (B19) infection during pregnancy is associated<SUP> </SUP>with the adverse foetal outcome known as non-immune hydrops<SUP> </SUP>fetalis (NIHF). Although B19 is known to infect erythroid-lineage<SUP> </SUP>cells <I>in vivo</I> as well as <I>in vitro</I>, the mechanism leading to<SUP> </SUP>the occurrence of NIHF is not clear. To investigate the possible<SUP> </SUP>involvement of the B19 non-structural protein NS1 in NIHF, three<SUP> </SUP>independent lines of transgenic mice were generated that expressed<SUP> </SUP>NS1 under the control of the Cre-<I>loxP</I> system and the GATA1 promoter.<SUP> </SUP>Two of the three lines expressed NS1 in erythroid-lineage cells.<SUP> </SUP>Most of the transgenic mice died at the embryonic stage, some<SUP> </SUP>of which developed hydropic changes caused by severe anaemia<SUP> </SUP>at embryonic day 15&#183;5 (E15&#183;5). Histological examination<SUP> </SUP>of embryos at E15&#183;5 showed significantly fewer erythropoietic<SUP> </SUP>islands in the liver parenchyma, whereas their hearts showed<SUP> </SUP>no abnormal signs, such as cardiomegaly and apoptotic cells.<SUP> </SUP>The NS1-transgenic mouse lines established here provide an animal<SUP> </SUP>model for human NIHF and suggest that NS1 plays a crucial role<SUP> </SUP>in the adverse outcome associated with intrauterine B19 infection<SUP> </SUP>in humans
Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Introduction<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


Replication of the pathogenic human parvovirus B19 is restricted<SUP> </SUP>to erythroid progenitor cells. Although blood group P antigen<SUP> </SUP>has been reported to be the cell surface receptor for parvovirus<SUP> </SUP>B19, a number of nonerythroid cells, which express P antigen,<SUP> </SUP>are not permissive for parvovirus B19 infection. We have documented<SUP> </SUP>that P antigen is necessary for parvovirus B19 binding but not<SUP> </SUP>sufficient for virus entry into cells. To test whether parvovirus<SUP> </SUP>B19 utilizes a cell surface coreceptor for entry, we used human<SUP> </SUP>erythroleukemia cells (K562), which allow parvovirus B19 binding<SUP> </SUP>but not entry. We report here that upon treatment with phorbol<SUP> </SUP>esters, K562 cells become adherent and permissive for parvovirus<SUP> </SUP>B19 entry, which is mediated by <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins, but only in their<SUP> </SUP>high-affinity conformation. Mature human red blood cells (RBCs),<SUP> </SUP>which express high levels of P antigen, but not <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins,<SUP> </SUP>bind parvovirus B19 but do not allow viral entry. In contrast,<SUP> </SUP>primary human erythroid progenitor cells express high levels<SUP> </SUP>of both P antigen and <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins and allow <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin&#150;mediated<SUP> </SUP>entry of parvovirus B19. Thus, in a natural course of infection,<SUP> </SUP>RBCs are likely exploited for a highly efficient systemic dissemination<SUP> </SUP>of parvovirus B19
To directly investigate whether cell adhesion renders cells<SUP> </SUP>susceptible to parvovirus B19 infection, we used the human erythroleukemia<SUP> </SUP>cell line K562 as a model system because these cells grow in<SUP> </SUP>suspension and can undergo a phenotype shift to adherent growth<SUP> </SUP>either spontaneously or upon prolonged treatment with phorbol<SUP> </SUP>esters.<SUP><A HREF="#REF18">18</A></SUP> We reported previously that these cells express P<SUP> </SUP>antigen and bind parvovirus B19 but cannot be transduced by<SUP> </SUP>recombinant parvovirus B19 vectors containing the firefly luciferase<SUP> </SUP>transgene (B19-Luc) when grown as suspension cultures.<SUP><A HREF="#REF17">17</A></SUP> In<SUP> </SUP>the present studies, we observed that spontaneously adherent<SUP> </SUP>and PMA&#150;treated K562 cells became permissive for parvovirus<SUP> </SUP>B19 infection. Using Cy3-labeled recombinant parvovirus B19<SUP> </SUP>particles and confocal microscopy, we documented binding but<SUP> </SUP>not internalization of Cy3-labeled parvovirus B19 particles<SUP> </SUP>(red) in K562 cells grown in suspension (Susp) cultures supplemented<SUP> </SUP>with divalent ions (Mn<SUP>2+</SUP> and Mg<SUP>2+</SUP>) (<A HREF="#FIG1">Figure 1A</A>). Upon spontaneous<SUP> </SUP>adherence (Adh) or PMA treatment (PMA), however, internalization<SUP> </SUP>and trafficking of parvovirus B19 particles to the nucleus (green)<SUP> </SUP>could be detected within the first 30 minutes of infection (<A HREF="#FIG1">Figure 1B-C</A>)<SUP> </SUP>as indicated by the yellow fluorescence of the nuclei.<SUP> </SUP>Importantly, in the absence of divalent ions, no internalization<SUP> </SUP>of parvovirus B19 particles could be observed (data not shown).<SUP> </SUP>Because PMA treatment did not affect the level of P antigen<SUP> </SUP>expression on these cells, as determined by flow cytometry (data<SUP> </SUP>not shown), we hypothesized that a cell surface factor(s) involved<SUP> </SUP>in cell adherence provided coreceptor activity for parvovirus<SUP> </SUP>B19 entry into human K562 cells
K562 cells express a very limited number of integrins, predominantly<SUP> </SUP><IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins.<SUP><A HREF="#REF19">19</A></SUP> No difference was found in the total levels<SUP> </SUP>of <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin expression or in the expression of specific activation-dependent<SUP> </SUP>epitopes on suspension, spontaneously adherent, and PMA-treated<SUP> </SUP>K562 cells by flow cytometry (data not shown). To test whether<SUP> </SUP><IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins were involved in the adhesion-dependent permissiveness<SUP> </SUP>of K562 cells for parvovirus B19 internalization, we incubated<SUP> </SUP>PMA-treated K562 cells in the presence of divalent ions and<SUP> </SUP>either <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin function-activating (or high-affinity conformation-stabilizing;<SUP> </SUP>N29, 21C8) or <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin function-blocking (or high-affinity<SUP> </SUP>conformation-destabilizing; P4C10, JB1a) antibodies prior to<SUP> </SUP>infection with Cy3-labeled or parvovirus B19-Luc vectors. Confocal<SUP> </SUP>microscopy revealed a reduction in nuclear localization of Cy3-labeled<SUP> </SUP>parvovirus B19 particles by <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin function-blocking antibodies<SUP> </SUP>(P4C10) 30 minutes after infection (<A HREF="#FIG2">Figure 2Ai-Aii</A>). In addition,<SUP> </SUP>transduction of PMA-treated K562 cells with recombinant parvovirus<SUP> </SUP>B19-Luc vectors was inhibited by 55.17% &#177; 0.22% and 65.22%<SUP> </SUP>&#177; 1.49% by preincubation of the cells with function-blocking<SUP> </SUP>monoclonal antibodies against <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5 and <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins, respectively<SUP> </SUP>(<A HREF="#FIG2">Figure 2B</A>). Interestingly, stabilization of the high-affinity<SUP> </SUP>conformation of surface-expressed <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins by monoclonal<SUP> </SUP>antibodies (N29, 21C8) resulted in an increase in parvovirus<SUP> </SUP>B19 entry and nuclear localization (<A HREF="#FIG2">Figure 2Aiii-Aiv</A>) as well<SUP> </SUP>as transduction (<A HREF="#FIG2">Figure 2B</A>) in PMA-treated K562 cells. Quantification<SUP> </SUP>of the confocal data revealed that 28.54% &#177; 4.68% of<SUP> </SUP>PMA-treated K562 cells showed nuclear entry of parvovirus B19<SUP> </SUP>in the absence of antibodies, compared with 58.06% &#177;<SUP> </SUP>1.09% and 57.86% &#177; 0.6%, respectively, in the presence<SUP> </SUP>of N29 and 21C8 high-affinity <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin&#150;stabilizing antibodies.<SUP> </SUP>In addition, activation of <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins by cross-linking of <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1<SUP> </SUP>integrin function-blocking antibodies with secondary goat antimouse<SUP> </SUP>IgG antibodies (JB1a+sec. Ab)<SUP><A HREF="#REF20">20</A></SUP> also resulted in an approximately<SUP> </SUP>3-fold increase in transduction (<A HREF="#FIG2">Figure 2B</A>). Because internalization<SUP> </SUP>of fibronectin by <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin is well documented, one possible<SUP> </SUP>mechanism of parvovirus B19 entry into human cells could be<SUP> </SUP>the internalization of fibronectin-opsonized viral particles.<SUP><A HREF="#REF19">19</A></SUP><SUP> </SUP>We examined, therefore, whether fibronectin binding to cell<SUP> </SUP>surface&#150;expressed <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins (which is mediated by the<SUP> </SUP>Arg-Gly-Asp [RGD]) containing tenth type III repeat of the central<SUP> </SUP>cell binding domain of fibronectin and inhibited by RGD peptides<SUP><A HREF="#REF21">21</A></SUP><SUP> </SUP>was necessary for parvovirus B19 infection. RGD peptides, however,<SUP> </SUP>in the absence (RGD) or presence of secondary antimouse IgG<SUP> </SUP>antibodies (RGD+sec. Ab) did not affect parvovirus B19 infection<SUP> </SUP>(<A HREF="#FIG2">Figure 2B</A>). These results suggested that <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins expressed<SUP> </SUP>on PMA-treated K562 cells and activated in the presence of divalent<SUP> </SUP>ions promoted the internalization of parvovirus B19 particles<SUP> </SUP>and that stabilization or destabilization of the high-affinity<SUP> </SUP>conformation of <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins using monoclonal antibodies modulated<SUP> </SUP>this coreceptor activity. In addition, these results indicated<SUP> </SUP>that fibronectin opsonization of parvovirus B19 particles was<SUP> </SUP>not involved in <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin&#150;mediated virus internalization<SUP> </SUP>and that the virus did not directly interact with the RGD ligand<SUP> </SUP>binding site on <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins. Furthermore, <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin coreceptor<SUP> </SUP>function could be enhanced either by increasing <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin affinity<SUP> </SUP>or avidity
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Case<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1>
 Wierenga KJJ, Pattison JR, Brink N <I>et al.</I> Glomerulonephritis after human parvovirus infection in homozygous sickle-cell disease. <I>Lancet</I> 1995; 346: 475&#150;476<!-- HIGHWIRE ID="14:10:2472:1" --><A HREF="/cgi/external_ref?access_num=A1995RP85700012&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7637482&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R2"><!-- null --></A>
<LI VALUE=2>
 Fawaz-Estrup F. Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. <I>J Rheumatol</I> 1996; 23: 1180&#150;1185<!-- HIGHWIRE ID="14:10:2472:2" --><A HREF="/cgi/external_ref?access_num=A1996UV68100011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8823689&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R3"><!-- null --></A>
<LI VALUE=3>
 Finkel TH, T&ouml;r&ouml;k TJ, Ferguson PJ <I>et al.</I> Chronic parvovirus B19 infection and systemic necrotizing vasculitis. Opportunistic infection or aetiological agent? <I>Lancet</I> 1994; 343: 1255&#150;1258<!-- HIGHWIRE ID="14:10:2472:3" --><A HREF="/cgi/external_ref?access_num=A1994NM14400010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7910276&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R4"><!-- null --></A>
<LI VALUE=4>
 Anderson MJ. Parvoviruses as agents of human disease. <I>Prog Med Virol</I> 1987; 34: 55&#150;69<!-- HIGHWIRE ID="14:10:2472:4" --><A HREF="/cgi/external_ref?access_num=A1987J829400003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2821578&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R5"><!-- null --></A>
<LI VALUE=5>
 Neild GH. Haemolytic uremic syndrome/thrombotic thrombocytopenic purpura: pathophysiology and treatment. <I>Kidney Int</I> 1998; 53 [Suppl 64]: S45&#150;S49<!-- HIGHWIRE ID="14:10:2472:5" --><!-- /HIGHWIRE -->
<A NAME="R6"><!-- null --></A>
<LI VALUE=6>
 Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementaemia. <I>Kidney Int</I> 1991; 39: 811<!-- HIGHWIRE ID="14:10:2472:6" --><A HREF="/cgi/external_ref?access_num=A1991FJ01800001&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1829775&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R7"><!-- null --></A>
<LI VALUE=7>
 Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. <I>Kidney Int</I> 1998; 53 [Suppl 66]: S54&#150;S57<!-- HIGHWIRE ID="14:10:2472:7" --><A HREF="/cgi/external_ref?access_num=000073285700011&link_type=ISI" >[ISI]</A><!-- /HIGHWIRE -->
</OL>

<FONT SIZE=-1>Received for publication: 26. 6.98</FONT><BR> 

<FONT SIZE=-1>Accepted in revised form: 28. 5.99
Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Human parvovirus B19 (B19) infects erythroid-lineage cells through<SUP> </SUP>P antigen and causes various clinical symptoms such as erythema<SUP> </SUP>infectiosum, anemia, polyarthritis, or fetal hydrops in humans.<SUP><A HREF="#REF1">1</A>,<A HREF="#REF2">2</A></SUP><SUP> </SUP>The cellular receptor for B19 infection has been regarded as<SUP> </SUP>blood group P antigen based on the failure of B19 infection<SUP> </SUP>in a patient with an hereditary defect of P antigen.<SUP><A HREF="#REF3">3</A></SUP> However,<SUP> </SUP>the target cells of B19 may be not be exclusively P-antigen&#150;positive<SUP> </SUP>erythroid-lineage cells, as illustrated by the poor relationship<SUP> </SUP>between P antigen expression levels and the efficiency of B19<SUP> </SUP>infection<SUP><A HREF="#REF4">4</A></SUP> or the failure of B19 binding to globoside.<SUP><A HREF="#REF5">5</A></SUP> Recently,<SUP> </SUP>Weigel-Kelley et al described the role of <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin as the<SUP> </SUP>cellular coreceptor for B19 infection.<SUP><A HREF="#REF6">6</A></SUP> The notion that B19<SUP> </SUP>receptor is not solely P antigen may be compatible with clinical<SUP> </SUP>findings that B19 has been detected in mononuclear cells of<SUP> </SUP>blood or tonsils with acute or prolonged B19 infection.<SUP><A HREF="#REF7">7</A>,<A HREF="#REF8">8</A></SUP> Also,<SUP> </SUP>following B19 infection, the numbers of peripheral blood lymphocytes<SUP> </SUP>may decrease despite undetectable levels of P antigen on their<SUP> </SUP>cell surface.<SUP><A HREF="#REF9">9</A>,<A HREF="#REF10">10</A></SUP> Finally, autoimmune-like phenomena including<SUP> </SUP>antinuclear antibodies, rheumatoid factors, or antiphospholipid<SUP> </SUP>antibodies are often associated with B19 infection,<SUP><A HREF="#REF8">8</A>,<A HREF="#REF11">11</A></SUP> and<SUP> </SUP>the levels of tumor necrosis factor <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> (TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">) and interferon <IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"><SUP> </SUP>(IFN-<IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0">) secreted from macrophages or T cells are elevated during<SUP> </SUP>acute or prolonged B19 infection.<SUP><A HREF="#REF12">12</A></SUP> Clinical studies have shown<SUP> </SUP>that B19 DNA can be amplified from joint samples by polymerase<SUP> </SUP>chain reaction (PCR),<SUP><A HREF="#REF13">13</A>,<A HREF="#REF14">14</A></SUP> and infective B19 was detected in<SUP> </SUP>the articular lesions of patients with rheumatoid arthritis.<SUP> </SUP>B19 transcripts and B19 protein viral protein 1 (VP1) were also<SUP> </SUP>present in T cells, B cells, macrophages, and follicular dendritic<SUP> </SUP>cells.<SUP><A HREF="#REF14">14</A></SUP> The cellular mechanism that may allow B19 binding and<SUP> </SUP>its entry into nonerythroid cells has not been elucidated. In<SUP> </SUP>the present study, we explored a putative receptor for B19 that<SUP> </SUP>was distinct from P antigen
Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Two parvoviruses of human origin, the nonpathogenic adeno-associated<SUP> </SUP>virus 2 (AAV) and the pathogenic parvovirus B19, have been studied<SUP> </SUP>extensively.<SUP><A HREF="#REF1">1</A>,<A HREF="#REF2">2</A></SUP> Recombinant AAV vectors have gained attention<SUP> </SUP>as a potentially useful alternative to the more commonly used<SUP> </SUP>recombinant retroviral and adenoviral vectors in human gene<SUP> </SUP>therapy.<SUP><A HREF="#REF3">3</A></SUP> AAV possesses a broad host range that transcends the<SUP> </SUP>species barrier because it utilizes the ubiquitously expressed<SUP> </SUP>cell surface heparan sulfate proteoglycan as a primary receptor<SUP> </SUP>for viral binding.<SUP><A HREF="#REF4">4</A></SUP> We and others have reported the requirement<SUP> </SUP>of fibroblast growth factor receptor 1 (FGFR1) and <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">V<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">5 integrin<SUP> </SUP>as coreceptors for viral entry.<SUP><A HREF="#REF5">5</A>,<A HREF="#REF6">6</A></SUP> Parvovirus B19, on the other<SUP> </SUP>hand, has been shown to have an extremely limited tissue-tropism,<SUP> </SUP>and the virus replication is restricted to human erythroid progenitor<SUP> </SUP>cells,<SUP><A HREF="#REF7">7</A></SUP> presumably because (1) the blood group P antigen (synonym<SUP> </SUP>"globoside"; "globotetraosylceramide") is used as primary cellular<SUP> </SUP>receptor for parvovirus B19,<SUP><A HREF="#REF8">8</A></SUP> (2) putative intracellular factors,<SUP> </SUP>largely restricted to human erythroid cells, are required for<SUP> </SUP>optimal transcriptional activation of the B19 promoter at map<SUP> </SUP>unit 6 (B19p6) and viral replication,<SUP><A HREF="#REF9">9</A>,<A HREF="#REF10">10</A></SUP> and (3) B19 capsid<SUP> </SUP>protein expression in nonpermissive cells is impaired due to<SUP> </SUP>a block in full-length transcription of the viral genome, atypical<SUP> </SUP>mRNA splicing, and impaired ribosome loading of structural gene<SUP> </SUP>transcripts.<SUP><A HREF="#REF11">11</A>-<A HREF="#REF13">13</A></SUP> However, P antigen expression is not restricted<SUP> </SUP>to erythroid cells, and a number of P antigen&#150;positive<SUP> </SUP>nonerythroid cells are nonpermissive for a successful infection<SUP> </SUP>by parvovirus B19.<SUP><A HREF="#REF2">2</A></SUP> In addition, mature red blood cells (RBCs),<SUP> </SUP>which are known to express high levels of P antigen, are unlikely<SUP> </SUP>to be ideal targets for B19 infection and replication because<SUP> </SUP>they lack nuclei. Similarly, B19p6 promoter-driven expression<SUP> </SUP>analyses were carried out with plasmid DNA transfections,<SUP><A HREF="#REF11">11</A>-<A HREF="#REF13">13</A></SUP><SUP> </SUP>which do not accurately reflect a natural infection by parvovirus<SUP> </SUP>B19
Bismuth H for the European FK-506 multicenter liver study group. Comparison of FK-506 and cyclosporine-based immunosuppression: FK-506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. Transplant Proc1995; 27: 45&#150;49<!-- HIGHWIRE ID="15:12:2059:1" --><A HREF="/cgi/external_ref?access_num=A1995QJ19900015&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7533415&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R2"><!-- null --></A>
<LI VALUE=2>
 van Besouw NM, van der Mast BJ, Smak Gregoor PJ <I>et al</I>. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant recipients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant1999; 14: 2710&#150;2713<!-- HIGHWIRE ID="15:12:2059:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ndt&resid=14/11/2710" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
<A NAME="R3"><!-- null --></A>
<LI VALUE=3>
 Crumpacker CS. Ganciclovir. New Eng J Med1996; 335: 721&#150;729<!-- HIGHWIRE ID="15:12:2059:3" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=335/10/721" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
<A NAME="R4"><!-- null --></A>
<LI VALUE=4>
 Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science1993; 262: 114&#150;117<!-- HIGHWIRE ID="15:12:2059:4" --><A HREF="/cgi/external_ref?access_num=A1993LZ63500036&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8211117&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R5"><!-- null --></A>
<LI VALUE=5>
 Yaegashi N, Ninuma T, Chisaka H <I>et al</I>. Parvovirus B19 infection induces apoptosis of erythroid cells <I>in vitro</I> and <I>in vivo</I>. J Infection1999; 39: 68&#150;76<!-- HIGHWIRE ID="15:12:2059:5" --><A HREF="/cgi/external_ref?access_num=000081946900011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10468132&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R6"><!-- null --></A>
<LI VALUE=6>
 Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugumara K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol1998; 72: 3018&#150;3028<!-- HIGHWIRE ID="15:12:2059:6" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jvi&resid=72/4/3018" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
<A NAME="R7"><!-- null --></A>
<LI VALUE=7>
 Moudgil A, Shidban H, Nast CC <I>et al</I>. Parvovirus B19 infection-related complications in renal transplant recipients. Transplantation1997; 64: 1847&#150;1850<!-- HIGHWIRE ID="15:12:2059:7" --><A HREF="/cgi/external_ref?access_num=000071404400037&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9422430&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R8"><!-- null --></A>
<LI VALUE=8>
 Wong T, Chan P, Leung C, Szeto C, Tam J, Li P. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis1999; 6: 1132&#150;1136<!-- HIGHWIRE ID="15:12:2059:8" --><!-- /HIGHWIRE -->
<A NAME="R9"><!-- null --></A>
<LI VALUE=9>
 Marchand S, Tchernia G, Hiesse C <I>et al</I>. Human parvovirus B19 infection in organ transplant recipients. Clin Transplant1999; 13: 17&#150;24<!-- HIGHWIRE ID="15:12:2059:9" --><A HREF="/cgi/external_ref?access_num=000079126100003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10081630&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
</OL>






		
        
        
	
	
	
	
	





 






<BR CLEAR=ALL>




  <FONT FACE="">
  
  </FONT>
<BR CLEAR=ALL>
<BR CLEAR=ALL>












<BR CLEAR=ALL>


	
	 
		
		  
			
	
		<table class="content_box_outer_table"
		 
			
				
					
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
			
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					
						
					
					<strong><a href="/cgi/content/extract/15/12/2059">
					Extract</a></strong>
					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				</td></tr>
			
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
		
	
	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/15/12/2059">
		<strong>FREE Full Text</strong> (PDF) <img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif"> </a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	





	
	
	

	
		
	

	 

	

	
	
		  
    

	
	
	
	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=ndt;15/12/2059&return_type=article&return_url=http%3A%2F%2Fndt.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2F15%2F12%2F2059">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=15/12/2059&return_type=article&return_url=http%3A%2F%2Fndt.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2F15%2F12%2F2059">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fndt.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2F15%2F12%2F2059&title=New-onset+anaemia+following+kidney+transplantation">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=ndt;15/12/2059&journalcode=ndt&minscore=20">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=ndt%3B15%2F12%2F2059&link_type=ISI_RelatedRecords">
				Similar articles in ISI Web of Science</a></strong>
			</td></tr>
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11096157&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		



			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/folders?action=addtofolder&wherefrom=JOURNALS&wrapped_id=ndt;15/12/2059">
				Add to My Personal Archive</a></strong>
			</td></tr>
		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=ndt;15/12/2059">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	

	
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong>
				Search for citing articles in:
				<br>
				<a href="/cgi/external_ref?access_num=ndt%3B15%2F12%2F2059&link_type=ISI_Citing">
				ISI Web of Science (1)</a>
				</strong>
			</td></tr>
		
	
		
		

		

	
	
	
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><A HREF="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org%2Fjnls%2Flist%2Fndt%2Fdisclaimer.html">Disclaimer</A></strong>
			</td></tr>
		

	
		

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/reprintspermissions?citation=Meeus+et+al.+15+%2812%29%3A+2059">
			Request Permissions</a></strong>
		</td></tr>
		
	

	







	
		
			
				
				
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Google Scholar</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AG.+author%3AMeeus%22">
							Articles by Meeus, G.</a></strong>
						</td></tr>
				
				
			
				
			
				
			
				
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AY.+author%3AVanrenterghem%22">
							Articles by Vanrenterghem, Y.</a></strong>
						</td></tr>
				
				
			
		
		
	
	
	
		
	
	





	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Meeus+G&link_type=AUTHORSEARCH">
							Articles by Meeus, G.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Vanrenterghem+Y&link_type=AUTHORSEARCH">
							Articles by Vanrenterghem, Y.</a></strong>
						</td></tr>
				
			
		

		
	

	
		
	





	






	






	
		

	

		
			
		
	 
		












	




	</td></tr></table>
</td></tr></table> 

					
					
	

<BR CLEAR=ALL>








	
</div>
</div>
<div id="secondary_footer">
<div id="issn">
Online ISSN 1460-2385 - Print ISSN 0931-0509
</div>
<div id="copyright">
<a href="/misc/terms.dtl">Copyright &copy;</a> 2005 <a href="http://www.era-edta.org/">European Renal Association - European Dialysis and Transplant Assoc</a>
</div>
</div>
<div id="primary_footer">
<div id="site_logo">
<strong><span>Oxford Journals</span></strong>
<em><span>Oxford University Press</span></em>
</div>
<div id="third_nav">
<ul>
<li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
<!-- <li><a href="http://www.oxfordjournals.org/terms_conditions.html">Terms &amp; Conditions</a></li> -->
<li><a href="http://www.oup.co.uk/privacy/">Privacy Policy</a></li>
<li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
</ul>
</div>
<div id="other_oup_sites">
<form action="http://www.oxfordjournals.org/service/redirect">
<div>
<label for="site_list">Other Oxford University Press sites:</label>
<select name="url" id="site_list">
<option value="http://www.oup.com/">Oxford University Press</option>
<option value="http://www.anb.org/">American National Biography</option>
<option value="http://www.oup.co.uk/booksellers/">Booksellers' Information Service</option>
<option value="http://www.oup.co.uk/oxed/children/">Children's Fiction and Poetry</option>
<option value="http://www.oup.co.uk/oxed/children/">Children's Reference</option>
<option value="http://www.oup.co.uk/corporate/">Corporate &amp; Special Sales</option>
<option value="http://www.oup.co.uk/dictionaries/">Dictionaries</option>
<option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
<option value="http://www.oup.co.uk/digital_reference/">Digital Reference</option>
<option value="http://www.oup.com/elt/">English Language Teaching</option>
<option value="http://www.oup.co.uk/best.textbooks/">Higher Education Textbooks</option>
<option value="http://www.oup.co.uk/academic/humanities/">Humanities</option>
<option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
<option value="http://www.oup.co.uk/law/">Law</option>
<option value="http://www.oup.co.uk/academic/medicine/">Medicine</option>
<option value="http://www.oup.co.uk/music/">Music</option>
<option value="http://www.oup.com/online">Online Products</option>
<option value="http://www.oed.com/">Oxford English Dictionary</option>
<option value="http://www.oup.co.uk/reference/">Reference</option>
<option value="http://www.oup.co.uk/rights/">Rights and Permissions</option>
<option value="http://www.oup.co.uk/academic/science/">Science</option>
<option value="http://www.oup.co.uk/oxed/">School Books</option>
<option value="http://www.oup.co.uk/academic/socsci/">Social Sciences</option>
<option value="http://www.oup.co.uk/general/vsi/">Very Short Introductions</option>
<option value="http://www.oup.co.uk/worldsclassics/">World's Classics
Parvovirus B19 infection has been found in several cell types<SUP> </SUP>including macrophages, follicular dendritic cells, T and B lymphocytes<SUP> </SUP>and endothelial cells, all potentially implicated in inflammatory<SUP> </SUP>muscle diseases. Surprisingly, infection of synoviocytes from<SUP> </SUP>RA patients following contact with parvovirus B19-infected cells<SUP> </SUP>induced or enhanced IL-6 production [<A HREF="#R8">8</A>]. The mode of infection<SUP> </SUP>of these synoviocytes has not been elucidated [<A HREF="#R15">15</A>], but in a<SUP> </SUP>recent study, parvovirus B19 induced invasive properties in<SUP> </SUP>normal human synoviocytes [<A HREF="#R16">16</A>]. In addition, IL-6 production<SUP> </SUP>can be induced in human haemopoietic cell lines stably transfected<SUP> </SUP>with DNA encoding the NS1 protein [<A HREF="#R17">17


Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Introduction <BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Methods <BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Results <BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Discussion <BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


To investigate whether cytokine responses may have a bearing<SUP> </SUP>on the symptoms and outcome of parvovirus B19 infection, circulating<SUP> </SUP>cytokines were measured during acute infection (<I>n</I>=51), follow-up<SUP> </SUP>of acute infection (<I>n</I>=39) and in normal healthy controls (<I>n</I>=50).<SUP> </SUP>At acute B19 virus infection (serum anti-B19 IgM-positive),<SUP> </SUP>patients ranged in age from 4 to 54 years, with a mean age of<SUP> </SUP>28&#183;2 years. The male:female ratio was 1:4&#183;1 and<SUP> </SUP>symptoms were rash (<I>n</I>=15), arthralgia (<I>n</I>=31), fatigue (<I>n</I>=8),<SUP> </SUP>lymphadenopathy (<I>n</I>=4), foetal hydrops (<I>n</I>=3), transient aplastic<SUP> </SUP>crisis (<I>n</I>=2), neutropenia (<I>n</I>=2), myelodysplasia (<I>n</I>=1), thrombocytopenia<SUP> </SUP>(<I>n</I>=1) and pancytopenia (<I>n</I>=1). Of these patients, 39 were contacted<SUP> </SUP>after a follow-up period of 2&#150;37 months (mean of 22&#183;5<SUP> </SUP>months). In comparison with normal controls, detectable IL-6<SUP> </SUP>was associated with acute B19 virus infection (26%; <I>P</I>=0&#183;0003),<SUP> </SUP>but not with follow-up (6%; <I>P</I>=0&#183;16). Detection of interferon<SUP> </SUP>(IFN)-<IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"> was associated with acute B19 virus infection (67%; <I>P</I>&lt;0&#183;0001)<SUP> </SUP>and follow-up (67%; <I>P</I>&lt;0&#183;0001). Detection of tumour<SUP> </SUP>necrosis factor (TNF)-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> was associated with acute B19 virus infection<SUP> </SUP>(49%; <I>P</I>&lt;0&#183;0001) and follow-up (56%; <I>P</I>&lt;0&#183;0001).<SUP> </SUP>IL-1<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0"> was detected in acute infection (20%), but not at follow-up.<SUP> </SUP>At acute B19 virus infection, detection of serum/plasma IL-6<SUP> </SUP>was associated with rheumatoid factor (<I>P</I>=0&#183;038) and IFN-<IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"><SUP> </SUP>(<IMG SRC="/math/ges.gif" ALT="&gt;=" BORDER="0">7&#160;pg/ml) was associated with fatigue in those patients<SUP> </SUP>of <IMG SRC="/math/ges.gif" ALT="&gt;=" BORDER="0">15 years of age (<I>P</I>=0&#183;022). At follow-up, fatigue was<SUP> </SUP>associated with IFN-<IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"> (<IMG SRC="/math/ges.gif" ALT="&gt;=" BORDER="0">7&#160;pg/ml) and/or TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> (<IMG SRC="/math/ges.gif" ALT="&gt;=" BORDER="0">40&#160;pg/ml)<SUP> </SUP>(<I>P</I>=0&#183;0275). Prolonged upregulation of serum IFN-<IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"> and<SUP> </SUP>TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> appears to represent a consistent host response to symptomatic<SUP> </SUP>B19 virus infection
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Materials and methods<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1>
 Nordborg E. Epidemiology of biopsy-positive giant cell arteritis: an overview. Clin Exp Rheumatol2000;18:S15&#150;S17.<!-- HIGHWIRE ID="41:4:445:1" --><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2>
 Weyand CM, Schonberger J, Oppitz U, Hunder NN, Hicok KC, Goronzy JJ. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med1994;179:951&#150;60.<!-- HIGHWIRE ID="41:4:445:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jem&resid=179/3/951" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3>
 Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern [see comments]. Ann Intern Med1995;123:192&#150;4.<!-- HIGHWIRE ID="41:4:445:3" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annintmed&resid=123/3/192" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4>
 Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark: association with epidemics of <I>Mycoplasma pneumoniae</I> infection. J Rheumatol1996;23:112&#150;9.<!-- HIGHWIRE ID="41:4:445:4" --><A HREF="/cgi/external_ref?access_num=A1996TN51400020&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8838518&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5>
 Russo MG, Waxman J, Abdoh AA, Serebro LH. Correlation between infection and the onset of the giant cell (temporal) arteritis syndrome. A trigger mechanism? Arthritis Rheum1995;38:374&#150;80.<!-- HIGHWIRE ID="41:4:445:5" --><A HREF="/cgi/external_ref?access_num=A1995QL61500011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7880192&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6>
 Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum1999;42:1255&#150;8.<!-- HIGHWIRE ID="41:4:445:6" --><A HREF="/cgi/external_ref?access_num=000080786000023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10366119&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7>
 Wagner AD, Gerard HC, Fresemann T <I>et al</I>. Detection of <I>Chlamydia pneumoniae</I> in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum2000;43:1543&#150;51.<!-- HIGHWIRE ID="41:4:445:7" --><A HREF="/cgi/external_ref?access_num=000088076700019&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10902759&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8>
 Hunder GG, Bloch DA, Michel BA <I>et al</I>. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum1990;33:1122&#150;8.<!-- HIGHWIRE ID="41:4:445:8" --><A HREF="/cgi/external_ref?access_num=A1990DV71700009&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2202311&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9>
 Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis1979;38:434&#150;9.<!-- HIGHWIRE ID="41:4:445:9" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annrheumdis&resid=38/5/434" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10>
 Kelsen J, Tarp B, Obel N. Absence of human herpes virus 8 in semen from healthy Danish donors. Hum Reprod1999;14:2274&#150;6.<!-- HIGHWIRE ID="41:4:445:10" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=humrep&resid=14/9/2274" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11>
 Eugen-Olsen J, Iversen AK, Garred P <I>et al</I>. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS1997;11:305&#150;10.<!-- HIGHWIRE ID="41:4:445:11" --><A HREF="/cgi/external_ref?access_num=A1997WK69200006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9147421&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12>
 Schowengerdt KO, Ni J, Denfield SW <I>et al</I>. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation1997;96:3549&#150;54.<!-- HIGHWIRE ID="41:4:445:12" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=circulationaha&resid=96/10/3549" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13>
 Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. &#145;Touchdown&#146; PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res1991;19:4008.<!-- HIGHWIRE ID="41:4:445:13" --><A HREF="/cgi/external_ref?access_num=A1991FY98700043&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1861999&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14>
 Gaydos CA, Eiden JJ, Oldach D <I>et al</I>. Diagnosis of <I>Chlamydia pneumoniae</I> infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis1994;19:157&#150;60.<!-- HIGHWIRE ID="41:4:445:14" --><A HREF="/cgi/external_ref?access_num=A1994NX66500026&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7948521&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15>
 Balin BJ, Gerard HC, Arking EJ <I>et al</I>. Identification and localization of <I>Chlamydia pneumoniae</I> in the Alzheimer's brain. Med Microbiol Immunol (Berl) 1998;187:23&#150;42.<!-- HIGHWIRE ID="41:4:445:15" --><A HREF="/cgi/external_ref?access_num=000075608700005&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9749980&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16>
 Gaydos CA, Quinn TC, Eiden JJ. Identification of <I>Chlamydia pneumoniae</I> by DNA amplification of the 16S rRNA gene. J Clin Microbiol1992;30:796&#150;800.<!-- HIGHWIRE ID="41:4:445:16" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcm&resid=30/4/796" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17>
 Tarp B, Kelsen J, Nielsen LP, Vinther B, Obel N. Herpesvirus type 1&#150;8 in sinus aspirates from human immunodeficiency virus type 1-infected patients and immunocompetent individuals. Rhinology2001;39:98&#150;102.<!-- HIGHWIRE ID="41:4:445:17" --><A HREF="/cgi/external_ref?access_num=000170064700009&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=11486447&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R18"><!-- null --></A>
<LI VALUE=18>
 Larson TS, Hall S, Hepper NG, Hunder GG. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med1984;101:594&#150;7.<!-- HIGHWIRE ID="41:4:445:18" --><A HREF="/cgi/external_ref?access_num=A1984TR73200003&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=6486590&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R19"><!-- null --></A>
<LI VALUE=19>
 Weyand CM, Schonberger J, Oppitz U, Hunder NN, Hicok KC, Goronzy JJ. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med1994;179:951&#150;60.<!-- HIGHWIRE ID="41:4:445:19" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jem&resid=179/3/951" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R20"><!-- null --></A>
<LI VALUE=20>
 Martinez-Taboada V, Hunder NN, Hunder GG, Weyand CM, Goronzy JJ. Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. J Mol Med1996;74:695&#150;703.<!-- HIGHWIRE ID="41:4:445:20" --><A HREF="/cgi/external_ref?access_num=A1996VT12500008&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8956156&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R21"><!-- null --></A>
<LI VALUE=21>
 Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Giant cell vasculitis is a T cell-dependent disease. Mol Med1997;3:530&#150;43.<!-- HIGHWIRE ID="41:4:445:21" --><A HREF="/cgi/external_ref?access_num=A1997XT68700005&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9307981&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R22"><!-- null --></A>
<LI VALUE=22>
 Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of <I>Chlamydia pneumoniae</I> in atherosclerotic lesions of coronary arteries. J Infect Dis1993;167:841&#150;9.<!-- HIGHWIRE ID="41:4:445:22" --><A HREF="/cgi/external_ref?access_num=A1993KU08600008&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8450249&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R23"><!-- null --></A>
<LI VALUE=23>
 Campbell LA, O'Brien ER, Cappuccio AL <I>et al</I>. Detection of <I>Chlamydia pneumoniae</I> TWAR in human coronary atherectomy tissues [see comments]. J Infect Dis1995;172:585&#150;8.<!-- HIGHWIRE ID="41:4:445:23" --><A HREF="/cgi/external_ref?access_num=A1995RK46400042&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7622912&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R24"><!-- null --></A>
<LI VALUE=24>
 Juvonen T, Juvonen J, Savolainen MJ. Is vasculitis a significant component of atherosclerosis? Curr Opin Rheumatol1999;11:3&#150;10.<!-- HIGHWIRE ID="41:4:445:24" --><A HREF="/cgi/external_ref?access_num=9894624&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R25"><!-- null --></A>
<LI VALUE=25>
 Kuo C, Campbell LA. Is infection with <I>Chlamydia pneumoniae</I> a causative agent in atherosclerosis? Mol Med Today1998;4:426&#150;30.<!-- HIGHWIRE ID="41:4:445:25" --><A HREF="/cgi/external_ref?access_num=000076388800006&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9793930&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R26"><!-- null --></A>
<LI VALUE=26>
 Staud R, Corman LC. Association of parvovirus B19 infection with giant cell arteritis. Clin Infect Dis1996;22:1123.<!-- HIGHWIRE ID="41:4:445:26" --><A HREF="/cgi/external_ref?access_num=A1996UQ79400051&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8783735&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R27"><!-- null --></A>
<LI VALUE=27>
 Zimmermann K, Mannhalter JW. Comparable sensitivity and specificity of nested PCR and single-stage PCR using a thermally activated DNA polymerase. Biotechniques1998;24:222&#150;4.<!-- HIGHWIRE ID="41:4:445:27" --><A HREF="/cgi/external_ref?access_num=000071909400011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9494719&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R28"><!-- null --></A>
<LI VALUE=28>
 Nordborg C, Nordborg E, Petursdottir V <I>et al</I>. Search for varicella zoster virus in giant cell arteritis. Ann Neurol1998;44:413&#150;4.<!-- HIGHWIRE ID="41:4:445:28" --><A HREF="/cgi/external_ref?access_num=000075744700022&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9749614&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></OL>

Submitted  18 December 2000; 

Accepted  7 November 2001
References
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Discussion<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>References</FONT><BR>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Calisher CH, Meurman O, Brummer-Korvenkontio M, Halonen PE, Muth DJ. Sensitive enzyme immunoassay for detecting immunoglobulin M antibodies to Sindbis virus and further evidence that Pogosta disease is caused by western equine encephalitis complex virus. J Clin Microbiol1985;22:566&#150;71.<!-- HIGHWIRE ID="39:11:1272:1" --><A HREF="/cgi/external_ref?access_num=A1985ARE3000023&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=3908469&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2> Brummer-Korvenkontio M, Kuusisto P. Onko Suomen l&auml;nsiosa s&auml;&auml;stynyt &#145;Pogostalta&#146;? [Has western Finland been spared the &#145;Pogosta&#146;?]. Suom L&auml;&auml;k&auml;ril1981;32:2606&#150;7.<!-- HIGHWIRE ID="39:11:1272:2" --><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3> Turunen M, Kuusisto P, Uggeldahl P-E, Toivanen A. Pogosta disease: clinical observations during an outbreak in the province of North Karelia, Finland. Br J Rheumatol1998;37:1177&#150;80.<!-- HIGHWIRE ID="39:11:1272:3" --><A HREF="/cgi/external_ref?access_num=000077263700008&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9851265&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4> Skogh M, Espmark &Aring;. Ockelbo-sjukan&#151;ett hud- och ledsyndrom troligen orsakat av myggburet alfa-arbovirus. L&auml;kartid1982;79:2379&#150;80.<!-- HIGHWIRE ID="39:11:1272:4" --><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5> Lvov DK, Skvortsova TM, Kondrashina NG <I>et al</I>. Etiology of Karelian fever, a new arbovirus infection. Vopr Virusol1982;6:690&#150;2.<!-- HIGHWIRE ID="39:11:1272:5" --><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6> Niklasson B, Espmark &Aring;. Ockelbo disease: arthralgia 3&#150;4 years after infection with a Sindbis virus related agent. Lancet1986;I:1039&#150;40.<!-- HIGHWIRE ID="39:11:1272:6" --><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7> Selden SM, Cameron AS. Changing epidemiology of Ross River virus disease in South Australia. Med J Aust1996;165:313&#150;7.<!-- HIGHWIRE ID="39:11:1272:7" --><A HREF="/cgi/external_ref?access_num=A1996VJ84500008&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=8862330&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8> H&ouml;rling J, Vene S, Franz&eacute;n C, Niklasson B. Detection of Ockelbo virus RNA in skin biopsies by polymerase chain reaction. J Clin Microbiol1993;31:2004&#150;9.<!-- HIGHWIRE ID="39:11:1272:8" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcm&resid=31/8/2004" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9> Melby PC, Darnell BJ, Tryon VV. Quantitative measurement of human cytokine gene expression by polymerase chain reaction. J Immunol Methods1993;159:235&#150;44.<!-- HIGHWIRE ID="39:11:1272:9" --><A HREF="/cgi/external_ref?access_num=A1993KQ29700027&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=7680366&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10> Halminen M, Sj&ouml;roos M, M&auml;kel&auml; MJ <I>et al</I>. Simultaneous detection of IFN-<I><IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"></I> and IL-4 mRNAs using RT-PCR and time-resolved fluorometry. Cytokine1999;11:87&#150;93.<!-- HIGHWIRE ID="39:11:1272:10" --><A HREF="/cgi/external_ref?access_num=000078781300012&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=10080884&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11> Nikkari S, Luukkainen R, M&ouml;tt&ouml;nen T <I>et al</I>. Does parvovirus B19 have a role in rheumatoid arthritis?. Ann Rheum Dis1994;53:106&#150;11.<!-- HIGHWIRE ID="39:11:1272:11" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annrheumdis&resid=53/2/106" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12> Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor&#150;recipient matching in cadaveric transplantation. Tissue Antigens1992;39:225&#150;35.<!-- HIGHWIRE ID="39:11:1272:12" --><A HREF="/cgi/external_ref?access_num=A1992HY72400001&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=1357775&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13> V&auml;limaa L, Sj&ouml;roos M, Luhtala M, Toivanen P, L&ouml;vgren T, Ilonen J. Detection of HLA-B27 alleles by group-specific amplification and time-resolved fluorometry. J Immunol Methods1998;219:131&#150;7.<!-- HIGHWIRE ID="39:11:1272:13" --><A HREF="/cgi/external_ref?access_num=000076899800011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9831394&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14> Nikkari S, Torvinen A, Hannonen P <I>et al</I>. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis1994;53:106&#150;11.<!-- HIGHWIRE ID="39:11:1272:14" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annrheumdis&resid=53/2/106" >[Abstract]</A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15> S&ouml;derlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet1997;349:1063&#150;5.<!-- HIGHWIRE ID="39:11:1272:15" --><A HREF="/cgi/external_ref?access_num=A1997WU00200011&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9107245&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16> Levine B, Hardwick JM, Griffin DE. Persistence of alphaviruses in vertebrate hosts. Trends Microbiol1994;2:25&#150;8.<!-- HIGHWIRE ID="39:11:1272:16" --><A HREF="/cgi/external_ref?access_num=8162433&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></OL>

Submitted   1 June 1999; 
revised version accepted 15 May 2000


The absence of IgM in our patient could be explained by the<SUP> </SUP>recurrence of parvovirus B19 infection in December 1996. However,<SUP> </SUP>the presence of specific IgM is not sufficient to link a parvovirus<SUP> </SUP>B19 infection to the diagnosis of DM. Viral detection directly<SUP> </SUP>at the site of the disease by PCR or Southern hybridization<SUP> </SUP>was therefore necessary. The presence of parvovirus B19 DNA<SUP> </SUP>in muscle biopsy was confirmed twice in our patient, using two<SUP> </SUP>different sets of primers. However, the extent of the contribution<SUP> </SUP>of a latent parvovirus B19 infection to myositis remains to<SUP> </SUP>be determined. Parvovirus B19 DNA has been shown to persist<SUP> </SUP>in synovial membrane, bone marrow or skin, not only in patients<SUP> </SUP>with autoimmune diseases or chronic urticaria but also in healthy<SUP> </SUP>immunocompetent individuals [<A HREF="#R12">12</A>&#150;<A HREF="#R14">14</A>]. Our control muscle<SUP> </SUP>samples were negative


In conclusion, this case is the first one to be reported depicting an
association between rituximab therapy and pure red cell<SUP> </SUP>aplasia.
Parvovirus B19 infection appears to be the linking factor<SUP> </SUP>in this
association, as described above. The development of chronic<SUP> </SUP>pure red
cell aplasia in a patient treated with rituximab should<SUP> </SUP>prompt a search
for parvovirus B19 infection. If detected, treatment<SUP> </SUP>with IVIg may cure
the infection in some patients and allow adequate<SUP> </SUP>control of viremia in
others, enabling them to become transfusion-independent.<SUP> </SUP>Such therapy
may need to be given intermittently for several months<SUP> </SUP>to these latter
patients until their humoral immunity recovers<SUP> </SUP>from the effects of
rituximab and clears the virus from circulation.<SUP> </SUP>Finally, with regard
to diagnosis, it is worth noting that B19<SUP> </SUP>infection in these patients
may not be detected by serologic testing<SUP> </SUP>due to their impaired antibody
response, as was the case with<SUP> </SUP>our patient. A PCR study to detect viral
DNA in serum should be<SUP> </SUP>performed. Indeed for any patient with chronic
pure red cell aplasia,<SUP> </SUP>parvovirus B19 infection should be ruled out by
PCR prior to embarking<SUP> </SUP>on immunosuppressive therapy aimed at treating
idiopathic or autoimmune<SUP> </SUP>forms of the disorder. Morphologic changes in
the bone marrow,<SUP> </SUP>if found, also help with the diagnosis. When in doubt,
a therapeutic<SUP> </SUP>trial of IVIg may be appropriate if definitive testing
for parvovirus<SUP> </SUP>B19 is not immediately<SUP> </SUP>available
More recently, we have generated recombinant parvovirus B19<SUP> </SUP>vectors in which a recombinant AAV genome is encapsidated into<SUP> </SUP>parvovirus B19 capsids.<SUP><A HREF="#REF16">16</A></SUP> Using these vectors, we established<SUP> </SUP>that P antigen is necessary for virus binding but not sufficient<SUP> </SUP>for virus entry into human cells because parvovirus B19 could<SUP> </SUP>bind to, but not enter, a number of P antigen&#150;expressing<SUP> </SUP>human cell lines.<SUP><A HREF="#REF17">17</A></SUP> During these studies, we observed that cells<SUP> </SUP>that grew as adherent monolayers were permissive for parvovirus<SUP> </SUP>B19 infection, whereas cells that grew as suspension cultures<SUP> </SUP>could not be infected, although both expressed P antigen and<SUP> </SUP>bound the virus, and we proposed that parvovirus B19 also requires<SUP> </SUP>the presence of a putative cell surface coreceptor for successful<SUP> </SUP>infection.<SUP><A HREF="#REF17">17
Since parvovirus B19 antibodies are highly prevalent in the<SUP> </SUP>normal population, with seroprevalence reaching 80&#150;100%<SUP> </SUP>at the age of 70, diagnosis based on serology alone can be difficult.<SUP> </SUP>On the other hand, as demonstrated by our quiz patient, a negative<SUP> </SUP>antibody status does not rule out infection in transplant recipients,<SUP> </SUP>especially in view of the trend to more potent immunosuppressive<SUP> </SUP>regimens, often including three different agents. Therefore,<SUP> </SUP>parvovirus B19 DNA detection on serum and bone marrow by the<SUP> </SUP>PCR technique should be carried out whenever parvovirus infection<SUP> </SUP>is suspected, since it is a treatable and possibly underestimated<SUP> </SUP>cause of anaemia in the immunocompromised host, that can be<SUP> </SUP>missed by serology alone. Parvovirus B19 infection can theoretically<SUP> </SUP>be treated by reducing immunosuppression. Some authors found<SUP> </SUP>tacrolimus to have an important role in defective parvovirus<SUP> </SUP>B19 clearance and report recovery by switching tacrolimus to<SUP> </SUP>cyclosporin A [<A HREF="#R8">8</A>]. When reducing or switching immunosuppression<SUP> </SUP>is unsuccessful, administration of intravenous immunoglobulin<SUP> </SUP>is the treatment of choice. The probable mechanism involves<SUP> </SUP>passive immunization, since high parvovirus B19 antibody titres<SUP> </SUP>have been demonstrated in commercial immunoglobulin preparations<SUP> </SUP>[<A HREF="#R9">9</A>]. Several therapeutic regimens have been proposed, ranging<SUP> </SUP>from 0.5 g/kg during 2 days to 0.4 g/kg during 10 days [<A HREF="#R9">9


Infection with parvovirus B19 produces a variety of clinical<SUP> </SUP>manifestations, from asymptomatic infection to respiratory tract<SUP> </SUP>illness, rash, joint affection and bone marrow suppression.<SUP> </SUP>In addition, the infection has been noted in patients with systemic<SUP> </SUP>vasculitis and inflammatory arthritis. One case of GCA and persistent<SUP> </SUP>parvovirus B19 infection with high titres and virus in the blood<SUP> </SUP>was reported by Staud and Corman [<A HREF="#R26">26</A>], but detection of virus<SUP> </SUP>in temporal biopsies was not attempted. Later, Gabriel <I>et al</I>.<SUP> </SUP>[<A HREF="#R6">6</A>] prospectively examined temporal artery biopsy tissue from<SUP> </SUP>a consecutive series of 50 patients for the presence of parvovirus<SUP> </SUP>B19. Parvovirus B19 DNA was present in seven (54%) of the 13<SUP> </SUP>biopsies from patients with GCA compared with only four (11%)<SUP> </SUP>of 37 biopsies from patients without GCA, suggesting the involvement<SUP> </SUP>of B19 in the pathogenesis
These findings are consistent with previous reports of long-term<SUP> </SUP>B19 virus DNA persistence following infection (Kerr, 2000<A HREF="#R19"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> )<SUP> </SUP>and with a state of immune activation in many individuals that<SUP> </SUP>may persist for years following acute B19 virus infection, possibly<SUP> </SUP>with the prime purpose of controlling B19 virus replication.<SUP> </SUP>Apoptosis is a feature of infection with various human and animal<SUP> </SUP>parvoviruses, including parvovirus B19 (Moffatt <I>et al.</I>, 1998<A HREF="#R26"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>), feline panleukopenia virus (Ikeda <I>et al.</I>, 1998<A HREF="#R16"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ), parvovirus<SUP> </SUP>H-1 (Ohshima <I>et al.</I>, 1998<A HREF="#R29"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ), CPV (Bauder <I>et al.</I>, 2000<A HREF="#R2"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ), minute<SUP> </SUP>virus of mice (MVMi) (Segovia <I>et al.</I>, 1999<A HREF="#R39"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ) and adeno-associated<SUP> </SUP>virus (AAV) (Zhou &amp; Trempe, 1999<A HREF="#R48"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> signalling<SUP> </SUP>pathway has been shown to be important in apoptosis due to parvoviruses<SUP> </SUP>H-1 (Rayet <I>et al.</I>, 1998<A HREF="#R35"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ) and B19 virus (Sol <I>et al.</I>, 1999<A HREF="#R42"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ).<SUP> </SUP>In the case of parvovirus H-1, virus-infected and NS1-expressing<SUP> </SUP>U937 promonocytic cells showed activation of CPP32 ICE-like<SUP> </SUP>cysteine protease with resultant apoptotic changes, in a manner<SUP> </SUP>similar to that resulting from exposure of these cells to TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"><SUP> </SUP>(Rayet <I>et al.</I>, 1998<A HREF="#R35"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). In the case of parvovirus B19, virus-infected<SUP> </SUP>and NS1-expressing erythroid cells were sensitised to TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">-induced<SUP> </SUP>apoptosis (Sol <I>et al.</I>, 1999


The two Namibian hand-raised cheetahs as well as the captured<SUP> </SUP>African wild cat and the captive Siberian tiger had never been<SUP> </SUP>vaccinated. However, all five captive cheetahs from United States<SUP> </SUP>zoos had recently been vaccinated with a killed multivalent<SUP> </SUP>vaccine. Two of these cheetahs had been vaccinated 1 month before<SUP> </SUP>death, one cheetah was vaccinated 1 year before death and the<SUP> </SUP>fourth cheetah was vaccinated 2 years previously, suggesting<SUP> </SUP>that inactivated FPV vaccines may not always produce a protective<SUP> </SUP>antibody response against challenge infections with canine parvovirus.<SUP> </SUP>Modified-live FPV virus vaccines have been shown to protect<SUP> </SUP>domestic cats against a challenge infection with a CPV-2b isolate<SUP> </SUP>(Chalmers <I>et al</I>., 1999<A HREF="#R4"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ) but experiments with an inactivated<SUP> </SUP>vaccine have never been reported. Vaccination of <I>Felidae</I> in<SUP> </SUP>Basel Zoo, Switzerland, with an inactivated CPV-2 vaccine has<SUP> </SUP>been described and the vaccine was well tolerated (Gutzwiller<SUP> </SUP>et al., 1984<A HREF="#R8"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). In our study six out of seven (86%) cases of<SUP> </SUP>parvovirus infections in large cats were caused by the new antigenic<SUP> </SUP>types of canine parvovirus. Vaccination of large cats in zoos<SUP> </SUP>against feline parvovirus is therefore strongly recommended<SUP> </SUP>and the development of inactivated CPV-2a or CPV-2b vaccines<SUP> </SUP>for use in large cats should be considered
Our patient had a complicated story, in keeping with the non-specific<SUP> </SUP>symptoms of many viral infections followed by a second phase<SUP> </SUP>of more specific system involvement. The blotchy maculo-papular<SUP> </SUP>skin rash was typical of parvovirus infection, and indeed is<SUP> </SUP>very unusual with HUS. Parvovirus infection can lead to a profound<SUP> </SUP>depletion of bone marrow precursors, as in patients with chronic<SUP> </SUP>haemolytic anaemias [<A HREF="#R4">4
Human parvovirus B19 is a small nonenveloped single-stranded DNA virus.
It is transmitted via respiratory droplets or, rarely,<SUP> </SUP>by blood
products.<SUP><a href="#B2">2</A></SUP> Infection is common: 15% of young children,<SUP> </SUP>50% to 60% of young adults, and up to 90% of the elderly population<SUP> </SUP>show IgG seropositivity. Parvovirus binds to the blood group P<SUP> </SUP>antigens (globoside),<SUP><a href="#B2">2</A></SUP> destroying erythroid
precursors. In<SUP> </SUP>childhood, it can cause erythema infectiousum ("fifth
disease"),<SUP> </SUP>hydrops fetalis, an acute polyarthropathy, or a transient
aplastic<SUP> </SUP>crisis.<SUP><a href="#B2">2</A></SUP> The normal immune system clears the
infection before<SUP> </SUP>there is prolonged symptomatic anemia. Patients with
lymphopenia<SUP> </SUP>secondary to HIV, or after transplantation,
chemotherapy, or chronic<SUP> </SUP>immunosuppressive therapy have the same
incidence of this common<SUP> </SUP>infection but may fail to clear parvovirus,
and may suffer from<SUP> </SUP>a chronic aplastic state and severe anemia.
Patients with reduced<SUP> </SUP>red-cell survival (eg, the chronic hemolytic
anemias) may suffer<SUP> </SUP>an acute aplastic crisis related to parvovirus B19.
Initial treatment<SUP> </SUP>of parvoviral PRCA usually consists of intravenous
immunoglobulin<SUP> </SUP>(IVIG) at doses equivalent to those used for immune
thrombocytopenic<SUP> </SUP>purpura
Regarding muscle diseases, several cases of myositis with the<SUP> </SUP>possible involvement of parvovirus B19 have been described.<SUP> </SUP>In two patients with a clinical picture highly suggestive of<SUP> </SUP>systemic lupus erythematosus, increased creatinine phosphokinase<SUP> </SUP>and aldolase levels were associated with acute parvovirus B19<SUP> </SUP>infection, as indicated by elevated IgM and IgG antibodies,<SUP> </SUP>but no viral examination was done in the muscle biopsy [<A HREF="#R9">9</A>].<SUP> </SUP>One child with recent onset of juvenile dermatomyositis showed<SUP> </SUP>serological evidence of acute parvovirus B19 infection. Amplification<SUP> </SUP>of viral DNA by PCR was positive in an early serum sample but<SUP> </SUP>was negative in muscle biopsy and peripheral blood leukocytes<SUP> </SUP>drawn at the time of biopsy [<A HREF="#R10">10</A>]. A 7-yr-old girl exposed to<SUP> </SUP>parvovirus B19 developed acute hepatitis and myositis followed<SUP> </SUP>by a life-threatening interstitial lung disease [<A HREF="#R11">11</A>]. Parvovirus<SUP> </SUP>B19 DNA in bone marrow, lung and serum and elevated IgM and<SUP> </SUP>IgG antibodies were detected. PCR-amplified viral DNA remained<SUP> </SUP>positive in serum until the end of the survey. Muscle biopsy<SUP> </SUP>showed type II fibre atrophy without significant inflammation,<SUP> </SUP>but parvovirus B19 DNA detection was not performed
We describe a 70-yr-old man who presented with bicytopenia and<SUP> </SUP>later with pancytopenia, vasculitis compatible with cutaneous<SUP> </SUP>polyarteritis nodosa and evidence for recent parvovirus B19<SUP> </SUP>infection. The seroprevalence of parvovirus in adults ranges<SUP> </SUP>between 30 and 60% [<A HREF="#R10">10</A>]. Thus, primary infection with the virus<SUP> </SUP>can occur at any age. Several diseases might explain the clinical<SUP> </SUP>presentation in this case. Primary necrotizing vasculitides<SUP> </SUP>are unlikely because they generally do not cause bone marrow<SUP> </SUP>suppression. Systemic lupus erythematosus is also unlikely as<SUP> </SUP>he was negative for ANA and the C3 level was normal. Acute bacterial<SUP> </SUP>endocarditis is unlikely because of the repeated negative blood<SUP> </SUP>cultures. Myelodysplastic syndrome (MDS) with cutaneous paraneoplastic<SUP> </SUP>manifestations, including vasculitis, has been reported [<A HREF="#R11">11</A>,<SUP> </SUP><A HREF="#R12">12</A>]. The clinical course of this patient, together with the<SUP> </SUP>need for recurrent red blood cell transfusion, is somewhat suggestive<SUP> </SUP>of MDS. However, the acute onset of the disease accompanied<SUP> </SUP>by fever and rash does not support this diagnosis. Also, the<SUP> </SUP>lack of chromosomal aberrations in the bone marrow is not compatible<SUP> </SUP>with MDS. Indeed, It is possible that the patient had subclinical<SUP> </SUP>MDS that was exacerbated by parvovirus infection


Because the results reported thus far were obtained using recombinant<SUP> </SUP>parvovirus B19 vectors, we next investigated the role of <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins<SUP> </SUP>in wild-type (wt) parvovirus B19 infection. Undifferentiated<SUP> </SUP>and PMA-differentiated K562 cells were infected with 500 ppc<SUP> </SUP>of wt parvovirus B19 for 1 hour and uninternalized viral particles<SUP> </SUP>were removed from the cell surface by trypsinization as described<SUP> </SUP>previously.<SUP><A HREF="#REF17">17</A></SUP> Internalized viral genomes were subsequently detected<SUP> </SUP>by Southern hybridization. As can be seen in <A HREF="#FIG3">Figure 3</A>, viral<SUP> </SUP>entry did not occur in undifferentiated K562 cells (<A HREF="#FIG3">Figure 3</A>,<SUP> </SUP>lane 2). Upon PMA treatment, however, single-stranded (ss) wt<SUP> </SUP>parvovirus B19 genomes were readily detected (<A HREF="#FIG3">Figure 3</A>, lane<SUP> </SUP>3). Pretreatment of wt parvovirus B19 with parvovirus B19 anti-VP2<SUP> </SUP>antibodies (<A HREF="#FIG3">Figure 3</A>, lane 4) or pretreatment of cells with<SUP> </SUP>inhibitory <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin antibody (P4C10) (<A HREF="#FIG3">Figure 3</A>, lane 5) abolished<SUP> </SUP>viral internalization. Interestingly, preincubation of PMA-treated<SUP> </SUP>K562 cells with <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin&#150;activating antibody (N29) increased<SUP> </SUP>the extent of wt parvovirus B19 internalization (<A HREF="#FIG3">Figure 3</A>, lane<SUP> </SUP>6). Despite successful entry, wt parvovirus B19 failed to undergo<SUP> </SUP>a productive replication (data not shown), suggesting the lack<SUP> </SUP>of erythroid cell&#150;specific transcriptional activators<SUP> </SUP>in PMA-differentiated K562 cells. These results, nonetheless,<SUP> </SUP>corroborate our observation that activated <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins play<SUP> </SUP>a crucial role in parvovirus B19 entry into human K562 cells
Discussion
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Case<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Discussion</FONT><BR>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Human parvovirus B19 is a small unenveloped DNA virus comprised<SUP> </SUP>of three structural polypeptides and a single-stranded DNA genome<SUP> </SUP>core [<A HREF="#R4">4</A>]. Infection in adults recently has been associated with<SUP> </SUP>sickle cell glomerulonephritis [<A HREF="#R1">1</A>], systemic lupus nephritis,<SUP> </SUP>chronic arthropathies [<A HREF="#R2">2</A>] and systemic necrotizing vasculitis<SUP> </SUP>[<A HREF="#R3">3</A>]. However, there have been no previous reports, to our knowledge,<SUP> </SUP>of HUS following human parvovirus infection in a previously<SUP> </SUP>fit man
The aplastic anaemia in our patient was caused by parvovirus<SUP> </SUP>B19 infection. Serum antibody detection, both IgG and IgM was<SUP> </SUP>negative on repeated occasions. However, direct detection of<SUP> </SUP>the S gene and the NS gene of parvovirus B19 by the PCR method<SUP> </SUP>was positive, both in serum and in bone marrow
An environmental infective trigger for GCA has long been suspected<SUP> </SUP>on the basis of the clinical presentation, as flu-like symptoms<SUP> </SUP>are often seen at the onset of disease and are followed by a<SUP> </SUP>marked acute-phase response [<A HREF="#R18">18</A>]. In addition, molecular studies<SUP> </SUP>of GCA have suggested a possible link between infection and<SUP> </SUP>GCA. Sequence analysis of the T-cell receptor of tissue-infiltrating<SUP> </SUP>T cells in lesions of temporal arteritis indicates restricted<SUP> </SUP>clonal expansion, suggesting that an antigen residing in the<SUP> </SUP>arterial wall is recognized by a small fraction of T cells [<A HREF="#R19">19</A>,<SUP> </SUP><A HREF="#R20">20</A>]. It has been demonstrated recently that the vascular lesions<SUP> </SUP>of GCA can be maintained in human artery&#150;mouse chimeras,<SUP> </SUP>indicating that all components necessary for the disease are<SUP> </SUP>present in the temporal artery [<A HREF="#R21">21</A>]. These findings suggest<SUP> </SUP>that a specific antigen, located within affected arteries, elicits<SUP> </SUP>the disease. In this work, we chose to investigate temporal<SUP> </SUP>biopsies for evidence of infection with <I>C. pneumoniae</I> and parvovirus<SUP> </SUP>B19, which have recently been associated with GCA [<A HREF="#R6">6</A>, <A HREF="#R7">7</A>]. As<SUP> </SUP>the disease has a predilection for elderly people, we hypothesized<SUP> </SUP>that reactivation of latent infection may play a role. The ability<SUP> </SUP>of herpes viruses to cause recrudescent or reactivated infection<SUP> </SUP>in the elderly and to provoke T-cell inflammation implicates<SUP> </SUP>these viruses also as possible disease triggers
Discussion
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Results<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Discussion</FONT><BR>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Since the discovery of blood group P antigen as a cellular receptor<SUP> </SUP>for parvovirus B19 in 1993,<SUP><A HREF="#REF8">8</A></SUP> it has been debated whether P antigen<SUP> </SUP>is necessary and sufficient for a successful infection by parvovirus<SUP> </SUP>B19 of its target erythroid progenitor cell. It would seem counterintuitive<SUP> </SUP>for the virus to evolve a strategy to use a cellular receptor<SUP> </SUP>that is expressed abundantly on mature erythrocytes, which lack<SUP> </SUP>nuclei. This would be tantamount to suicide, for parvovirus<SUP> </SUP>B19 replication is absolutely dependent on the nucleus and all<SUP> </SUP>the replication machinery contained therein. In our previously<SUP> </SUP>published studies, we had shown that P antigen is necessary<SUP> </SUP>for binding but not sufficient for B19 entry.<SUP><A HREF="#REF17">17</A></SUP> We also observed<SUP> </SUP>that parvovirus B19-susceptible cells had an adherent phenotype,<SUP> </SUP>whereas resistant cells grew as suspension cultures.<SUP><A HREF="#REF17">17</A></SUP> We document<SUP> </SUP>here that a phenotype shift from nonadherent to adherent growth<SUP> </SUP>renders the erythroleukemia cell line K562 susceptible to parvovirus<SUP> </SUP>B19 infection. Using PMA treatment, divalent ions (Mn<SUP>2+</SUP>), and<SUP> </SUP>high-affinity conformation-stabilizing and -destabilizing <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1<SUP> </SUP>integrin antibodies, we demonstrate that activated <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins<SUP> </SUP>facilitate parvovirus B19 entry into K562 cells. Mn<SUP>2+</SUP> ions activate<SUP> </SUP><IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins by overcoming structural restraints that maintain<SUP> </SUP><IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins in a low-affinity state,<SUP><A HREF="#REF22">22</A>,<A HREF="#REF23">23</A></SUP> and function-activating<SUP> </SUP>antibodies stabilize this high-affinity conformation.<SUP><A HREF="#REF20">20
Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Methods<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Human parvovirus B19 (B19) was discovered in the sera of healthy<SUP> </SUP>blood donors (Cossart <I>et al.</I>, 1975<A HREF="#R8"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ) and was defined to be the<SUP> </SUP>causative agent of erythema infectiosum (fifth disease) in children<SUP> </SUP>(Anderson <I>et al.</I>, 1983<A HREF="#R1"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ) and polyarthropathy syndrome in adults<SUP> </SUP>(Brown &amp; Young, 1997<A HREF="#R4"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). B19 is a small, single-stranded<SUP> </SUP>DNA virus and is characterized by its target specificity for<SUP> </SUP>human erythroid-lineage cells, which is due in part to the distribution<SUP> </SUP>of its receptor, the P antigen (Brown <I>et al.</I>, 1993<A HREF="#R6"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> , 1994<A HREF="#R7"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ).<SUP> </SUP>B19 infection causes human aplastic conditions, such as chronic<SUP> </SUP>anaemia in immunocompromised hosts, transient aplastic crisis<SUP> </SUP>and probably some cases of non-immune hydrops fetalis (NIHF)<SUP> </SUP>(Brown <I>et al.</I>, 1984<A HREF="#R5"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Yaegashi <I>et al.</I>, 1999<A HREF="#R42"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Young, 1988<A HREF="#R43"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ).<SUP> </SUP>The anaemia induced by B19 infection is of minor clinical significance<SUP> </SUP>in healthy children and adults; however, it becomes critical<SUP> </SUP>in those afflicted with haemolytic diseases, such as sickle<SUP> </SUP>cell anaemia, hereditary spherocytosis and thalassaemia (Kelleher<SUP> </SUP><I>et al.</I>, 1983<A HREF="#R11"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Levy <I>et al.</I>, 1997<A HREF="#R14"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The pathogenesis of aplastic<SUP> </SUP>crisis in patients with haemolytic disease is accounted for<SUP> </SUP>by the short life-span of red blood cells. The turnover of erythroid-lineage<SUP> </SUP>cells is rapid in these patients and B19 infection induces the<SUP> </SUP>acceleration of death of erythroid-lineage cells, resulting<SUP> </SUP>in severe anaemia (Kelleher <I>et al.</I>, 1983<A HREF="#R11"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Levy <I>et al.</I>, 1997<A HREF="#R14"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>). Similarly, foetuses are thought to be severely affected,<SUP> </SUP>particularly during the early hepatic stage of haematopoiesis,<SUP> </SUP>as the half-life of red blood cells is apparently shorter in<SUP> </SUP>this haematopoietic stage compared with the later bone marrow/splenic<SUP> </SUP>haematopoietic stage (Yaegashi <I>et al.</I>, 1989<A HREF="#R39"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> , 1998<A HREF="#R41"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The risk<SUP> </SUP>of an adverse foetal outcome is approximately 10% when mothers<SUP> </SUP>are infected with B19, and increases if maternal infection occurs<SUP> </SUP>during the first 20 weeks of gestation (Miller <I>et al.</I>, 1998<A HREF="#R15"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>; Yaegashi <I>et al.</I>, 1998<A HREF="#R41"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). Epidemiological studies have also<SUP> </SUP>shown that intrauterine B19 infection is causatively related<SUP> </SUP>to NIHF and intrauterine foetal death without malformations<SUP> </SUP>(Brown <I>et al.</I>, 1984<A HREF="#R5"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Miller <I>et al.</I>, 1998<A HREF="#R15"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Yaegashi <I>et al.</I>,<SUP> </SUP>1994<A HREF="#R40"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). However, the mechanism of induction of NIHF by B19 infection,<SUP> </SUP>the cause of the severe anaemia, has not yet been clarified
Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Introduction<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


Human parvovirus B19 (B19) infects human erythroid cells expressing<SUP> </SUP>P antigen. However, some cell lines that were positive for P<SUP> </SUP>antigen failed to bind B19, whereas some cell lines had an ability<SUP> </SUP>to bind B19 despite undetectable expression of P antigen. We<SUP> </SUP>here demonstrate that B19 specifically binds with Ku80 autoantigen<SUP> </SUP>on the cell surface. Furthermore, transfection of HeLa cells<SUP> </SUP>with the gene of Ku80 enabled the binding of B19 and allowed<SUP> </SUP>its entry into cells. Moreover, reduction of cell-surface expression<SUP> </SUP>of Ku80 in KU812Ep6 cells, which was a high-sensitive cell line<SUP> </SUP>for B19 infection, by short interfering RNA for Ku80 resulted<SUP> </SUP>in the marked inhibition of B19 binding in KU812Ep6 cells. Although<SUP> </SUP>Ku80 originally has been described as a nuclear protein, human<SUP> </SUP>bone marrow erythroid cells with glycophorin A or CD36, B cells<SUP> </SUP>with CD20, or T cells with CD3 were all positive for cell-surface<SUP> </SUP>expression of Ku80. B19 infection of KU812Ep6 cells and bone<SUP> </SUP>marrow cells was inhibited in the presence of anti-Ku80 antibody.<SUP> </SUP>Our data suggest that Ku80 functions as a novel coreceptor for<SUP> </SUP>B19 infection, and this finding may provide an explanation for<SUP> </SUP>the pathologic immunity associated with B19 infection


Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Case<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Human parvovirus infection recently has been increasingly described<SUP> </SUP>in association with various glomerulonephritides [<A HREF="#R1">1</A>&#150;<A HREF="#R3">3</A>].<SUP> </SUP>To the best of our knowledge, there have been no previous reports<SUP> </SUP>of haemolytic&#150;uraemic syndrome (HUS) following parvovirus<SUP> </SUP>infection in a previously fit man


Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Materials and methods<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Note added in proof<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Human parvovirus B19 (B19) is the aetiological agent of the<SUP> </SUP>rash illness erythema infectiosum, which may be complicated<SUP> </SUP>by arthralgia and arthritis [<A HREF="#R1">1</A>]. B19 infection in patients with<SUP> </SUP>shortened red cell survival has been associated with temporary<SUP> </SUP>cessation of erythropoiesis and life-threatening anaemia. B19<SUP> </SUP>infection during pregnancy has been associated with fetal B19<SUP> </SUP>infection, hydrops fetalis and death. Persistent B19 infections<SUP> </SUP>have been reported most frequently in persons with underlying<SUP> </SUP>immunodeficiency [<A HREF="#R1">1</A>]. B19 infection has also been associated<SUP> </SUP>with arthropathy following acute infection, which may be present<SUP> </SUP>for months to years [<A HREF="#R1">1</A>]. A recent report provides compelling<SUP> </SUP>evidence for a causative role for B19 virus in rheumatoid arthritis<SUP> </SUP>(RA) [<A HREF="#R2">2</A>], although findings of other groups are conflicting<SUP> </SUP>[<A HREF="#R3">3</A>]. Other diseases which have been associated with B19 infection<SUP> </SUP>are cardiac disease, hepatobiliary tract disease, neurological<SUP> </SUP>syndromes, ocular disease, renal disease, lower respiratory<SUP> </SUP>tract disease and chronic fatigue syndrome (CFS
Recently, an expanding spectrum of clinical disease has been<SUP> </SUP>attributed to human parvovirus B19 (B19) infection with adult<SUP> </SUP>seroprevalence rates of around 50% [<A HREF="#R1">1</A>]. In the majority of cases,<SUP> </SUP>B19 infections may be subclinical or produce symptoms such as<SUP> </SUP>erythema infectiosum, aplastic anaemia and thrombocytopenia<SUP> </SUP>and rarely as acute hepatic dysfunction. The common aetiologic<SUP> </SUP>factors of acute hepatic dysfunction following kidney transplantation<SUP> </SUP>include viral infection such as hepatitis B virus (HBV), hepatitis<SUP> </SUP>C virus (HCV) infection, cytomegalovirus (CMV), herpes simplex,<SUP> </SUP>varicella and Epstein-Barr virus, immunosuppressive drugs such<SUP> </SUP>as azathioprine, cyclosporin A and tacrolimus [<A HREF="#R2">2</A>]. We report<SUP> </SUP>a kidney transplant with probable relapse of B19 infection associated<SUP> </SUP>with acute hepatic dysfunction and successfully treated with<SUP> </SUP>intravenous immunoglobulin
AUTOIMMUNE neutropenia (AIN) is a
disorder caused by increased peripheral destruction of neutrophils as a
result of antibodies in the patient's blood that are directed against
their own neutrophils. It could not be convincingly shown until 1975
that neutropenia can be caused by granulocyte-specific
autoantibodies.<SUP><a href="#B1">1</A></SUP><SUP>,</SUP><SUP><a href="#B2">2</A></SUP> Primary AIN, which is not associated
with other diseases such as systemic lupus erythematosus, is often
observed in infants.<SUP><a href="#B3">3</A></SUP><SUP>,</SUP><SUP><a href="#B4">4</A></SUP> Although the etiology of the
disease is unknown, a recent report about a possible association of AIN
with Parvovirus B19 infection<SUP><a href="#B5">5</A></SUP> resulted in frequent testing
for this virus in patients with suspected AIN. Because of the
difficulties with the detection of granulocyte autoantibodies, many
questions concerning clinical course, diagnostic approach, immunology,
and therapy have remained open. In contrast to severe chronic
neutropenias (SCN) caused by disorders of myelopoiesis,<SUP><a href="#B6">6</A></SUP>
AIN in infancy is less often considered in standard textbooks of
pediatric hematology. As a result, AIN is less known among physicians
and many cases are only diagnosed after expensive and burdening
investigations excluding other forms of neutropenia. This and the
availability of recombinant human granulocyte colony-stimulating factor
(G-CSF) for treatment of chronic neutropenia<SUP><a href="#B6">6</A></SUP> make an
accurate diagnosis of AIN necessary. Therefore, we evaluated the data
of 240 infants with primary AIN


Primary autoimmune neutropenia (AIN) is caused by
granulocyte-specific autoantibodies and occurs predominantly in
infancy. Clinical presentation and diagnosis have not been well
established, resulting in burdening diagnostic investigations and
unnecessary treatment with granulocyte colony-stimulating factor
(G-CSF). In the present study, clinical, laboratory, and immunologic
data of 240 infants with primary AIN were evaluated. Suspected
association with parvovirus B19 infection was investigated using
serologic and DNA-based methods. Primary AIN was mainly diagnosed at
the age of 5 to 15 months but was observed as early as day 33 of life.
In 90% of the cases, AIN was associated with benign infections despite
severe neutropenia. Spontaneous remission, shown by 95% of the
patients, usually occurred within 7 to 24 months. Autoantibodies in the
patient's sera were not always present, and screening had to be
repeated several times until antibody detection succeeded. About 35%
of the autoantibodies showed preferential binding to granulocytes from
NA1 and NA2 homozygous donors. Bone marrow was typically normocellular
or hypercellular, with a variably diminished number of segmented
granulocytes. A significant association with parvovirus B19 infection
was not found. Symptomatic treatment with antibiotics was sufficient in
most patients. Eighty-nine percent of the patients received antibiotics
(cotrimoxazole) for prophylaxis of infections. For severe infections or
for surgical preparation, G-CSF, corticosteroids, and intravenous IgG
were administered, resulting in increased neutrophil counts in 100%,
75%, and 50% of the patients treated, respectively. In combination
with the detection of granulocyte-specific antibodies, the typical
clinical picture allowed diagnosis of AIN without burdening
investigations. Treatment with G-CSF was found to be a reliable
alternative to temporarily increase the neutrophil count


Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Methods<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Until now, parvovirus B19 is the only member of the <I>Parvoviridae<SUP> </SUP></I>known to cause disease in humans. It was discovered in 1975<SUP> </SUP>by Cossart <I>et al.</I> (1975)<A HREF="#R6"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A>  and was associated with the common<SUP> </SUP>childhood disease erythema infectiosum or fifth disease some<SUP> </SUP>years later (Anderson <I>et al.</I>, 1983<A HREF="#R1"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). Furthermore, acute and<SUP> </SUP>chronic polyarthralgia (Naides <I>et al.</I>, 1990<A HREF="#R20"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Reid <I>et al.</I>, 1985<A HREF="#R23"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>) and arthritis (Ueno <I>et al.</I>, 1993<A HREF="#R33"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ) are frequently associated<SUP> </SUP>with parvovirus B19 infections, particularly in adult women.<SUP> </SUP>Depending on the patient&#146;s haematological and immunological<SUP> </SUP>status, B19 infections can provoke a variety of additional,<SUP> </SUP>more severe clinical symptoms: frequent complications occur<SUP> </SUP>in patients with underlying haemolytic disorders, which show<SUP> </SUP>a high tendency to develop aplastic crises (Serjeant <I>et al.</I>,<SUP> </SUP>1993<A HREF="#R29"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). Establishment of persistent parvovirus B19 infections<SUP> </SUP>has been reported in patients both with and without underlying<SUP> </SUP>immunodeficiencies (Pont <I>et al.</I>, 1992<A HREF="#R22"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Anderson <I>et al.</I>, 1985<A HREF="#R2"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>; Kurtzman <I>et al.</I>, 1987<A HREF="#R16"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). Persistence is thought to be due<SUP> </SUP>to a qualitatively or quantitatively inadequate humoral immune<SUP> </SUP>response (Foto <I>et al.</I>, 1993<A HREF="#R9"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Kurtzman <I>et al.</I>, 1989<I>a</I><A HREF="#R17"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). In particular,<SUP> </SUP>the response directed to the VP1-specific parts of the structural<SUP> </SUP>proteins seems to be absent in these cases (Kurtzman <I>et al.</I>,<SUP> </SUP>1989<I>a</I><A HREF="#R18"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> , <I>b</I><A HREF="#R18"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The pathogenic mechanisms underlying leukopenias<SUP> </SUP>and arthritis are not known. Since replication of B19 virus<SUP> </SUP>is strongly restricted to the erythroid progenitor cells in<SUP> </SUP>the bone marrow, it is not clear how the virus causes destruction<SUP> </SUP>of other cells. Further complications of acute infection may<SUP> </SUP>occur in pregnant women, since the virus may be transmitted<SUP> </SUP>to the foetus and infection <I>in utero</I> can cause hydrops foetalis<SUP> </SUP>and foetal death (Brown <I>et al.</I>, 1984
The human promonocytic cell line U937 is highly sensitive to the lytic effect of the autonomous parvovirus H-1. Rare cell variants that resisted H-1 virus infection could be isolated, of which four (RU1, RU2, RU3, and RU4) were further characterized. In contrast to parental cells, the RU clones sustained an abortive H-1 virus infection. Three of the clones showed a significant decrease in the accumulation levels of the c-Myc oncoprotein and in their capacity for forming tumors in immunodeficient mice. Surprisingly, all RU clones resisted the suppressing effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on c-<I>myc</I> oncogene expression and cell proliferation. In contrast, RU clones exhibited the TPA-induced changes in membrane surface antigens and nonspecific esterase activities that are characteristic of monocytic differentiation. Studies of the activation steady-state of RU cells demonstrated the constitutive production of significant amounts of nitric oxide (NO) and superoxide anion (O<SUP>-</SUP><SUB>2<SUP>.</SUP></SUB> ). Inhibitors of NO and O<SUP>-</SUP><SUB>2<SUP>.</SUP></SUB> . production sensitized all RU cells to the killing effect of parvovirus H-1 and increased the production of infectious viral particles. These data argue for the participation of active oxygen species in macrophage defence mechanisms against parvovirus infection. Moreover, the use of parvovirus H-1 as a selective agent in a cell-colony formation assay allowed us to show that expression of defined markers of monocytic differentiation can be uncoupled from suppression of proliferation
Parvovirus B19 replication takes place in the cell nucleus,<SUP> </SUP>making mature red cells (RBCs) poor targets for parvovirus B19<SUP> </SUP>infection. However, RBCs express high levels of P antigen, the<SUP> </SUP>primary receptor for parvovirus B19.<SUP><A HREF="#REF8">8</A></SUP> Flow cytometric analysis<SUP> </SUP>of normal donor RBCs (<A HREF="#FIG5">Figure 5A</A>) confirmed high-level expression<SUP> </SUP>of P antigen (<A HREF="#FIG5">Figure 5A</A>, left) and documented the complete absence<SUP> </SUP>of <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5 (<A HREF="#FIG5">Figure 5A</A>, middle) and <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 (<A HREF="#FIG5">Figure 5A</A>, right) integrins.<SUP> </SUP>Furthermore, although parvovirus B19 bound efficiently to these<SUP> </SUP>cells, as detected by confocal microscopy (<A HREF="#FIG5">Figure 5Bi</A>), treatment<SUP> </SUP>with trypsin almost completely removed parvovirus B19 particles<SUP> </SUP>bound to these cells, suggesting that most viral particles did<SUP> </SUP>not enter the RBCs (<A HREF="#FIG5">Figure 5Bii<!-- HIGHWIRE EXLINK_ID="102:12:3927:1" VALUE="5Bii" TYPEGUESS="PDB" --><!-- /HIGHWIRE --></A>). It is important to emphasize<SUP> </SUP>that we have previously documented complete removal of uninternalized<SUP> </SUP>parvoviral particles by the trypsin treatment,<SUP><A HREF="#REF17">17</A></SUP> and this treatment<SUP> </SUP>had no adverse effects on RBC viability, as determined by trypan<SUP> </SUP>blue exclusion assays (2.97% trypan blue&#150;positive untreated<SUP> </SUP>RBCs versus 3.34% trypan blue&#150;positive trypsin-treated<SUP> </SUP>RBCs, respectively). These results substantiate our hypothesis<SUP> </SUP>that <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin serves as a coreceptor for parvovirus B19 entry<SUP> </SUP>into human cells
Human parvovirus B19 is ubiquitous and is responsible for erythema<SUP> </SUP>infectiosum (fifth disease) in children.<SUP><A HREF="#REF39">39</A></SUP> Because this infection<SUP> </SUP>is common,<SUP><A HREF="#REF40">40</A></SUP> seroconversion from a community-acquired infection<SUP> </SUP>is most likely. Parvovirus B19 seroprevalence was shown to be<SUP> </SUP>32% in age-matched control pediatric patients with hemophilia<SUP> </SUP>who had not previously received transfusions of blood products.<SUP><A HREF="#REF41">41</A></SUP><SUP> </SUP>Furthermore, human parvovirus B19 has resisted cultivation in<SUP> </SUP>conventional cell lines, including CHO cells, which are used<SUP> </SUP>to manufacture rFIX.<SUP><A HREF="#REF42">42</A></SUP> Also, viral clearance studies used to<SUP> </SUP>validate the rFIX purification process demonstrate significant<SUP> </SUP>removal of all model viruses tested, including bovine parvovirus<SUP> </SUP>(overall log<SUB>10</SUB> removal value of 12.0), which is the model for<SUP> </SUP>the virus class that includes human parvovirus B19 (Data on<SUP> </SUP>file at Wyeth Pharmaceuticals). Therefore, the prevalence of<SUP> </SUP>this disease in the community, coupled with the safeguards built<SUP> </SUP>into the manufacturing process of rFIX, make it highly unlikely<SUP> </SUP>that parvovirus B19 infection via rFIX administration can be<SUP> </SUP>the cause of seroconversion
Koduri PR, Patel AR, Pinar H. Acute hepatic sequestration caused by parvovirus B19 infection in a patient with sickle cell anemia. Am J Hematol. 1994;47: 250-251.<!-- HIGHWIRE ID="103:2:422:6" --><A HREF="/cgi/external_ref?access_num=7942800&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7942800&displayid=77140&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve


The majority of patients with mutations of CD40L had the typical<SUP> </SUP>phenotype of X-linked HIGM characterized by early onset of severe<SUP> </SUP>recurrent sinopulmonary infections, including PCP, and the development<SUP> </SUP>of cholangitis associated with persistent <I>cryptosporidium</I> infection,<SUP> </SUP>with or without neutropenia. Response to intravenous immunoglobulin<SUP> </SUP>therapy was less than optimal in some patients. Exceptions were<SUP> </SUP>6 male patients with a mild phenotype, late onset of symptoms,<SUP> </SUP>and no history of PCP, <I>cryptosporidium</I> infection, or neutropenia<SUP> </SUP>(<A HREF="#TBL3">Table 3</A>). Three of the 6 atypical cases (patients 61-63) had<SUP> </SUP>the same amino acid substitution (Thr254Met) affecting the carboxy<SUP> </SUP>terminal of exon 5. One patient had a nonsense mutation (Arg11stop)<SUP> </SUP>that resulted in truncation of the intracellular domain. Patient<SUP> </SUP>17 had an in-frame deletion of exon 2 (44 amino acids) due to<SUP> </SUP>a splice site mutation (IVS2 + 2t&gt;a) resulting in the production<SUP> </SUP>of a small population of wild-type mRNA, presumably enough to<SUP> </SUP>generate a low number of functionally normal CD40L homotrimeric<SUP> </SUP>molecules.<SUP><A HREF="#REF31">31</A>,<A HREF="#REF35">35</A></SUP> The last of the atypical patients (no. 19) had<SUP> </SUP>a "silent" point mutation (367G&gt;A) affecting the last nucleotide<SUP> </SUP>of exon 3, causing a splicing defect that results in skipping<SUP> </SUP>of exon 3 and frameshift, but also in the production of a small<SUP> </SUP>amount of normally spliced wild-type mRNA. Activated T cells<SUP> </SUP>from 3 of these 6 individuals with a mild phenotype were able<SUP> </SUP>to bind CD40-Ig fusion protein although at reduced quantity.<SUP> </SUP>Patients 1, 17, and 19 were asymptomatic until they presented<SUP> </SUP>with pure red cell aplasia caused by chronic parvovirus B19<SUP> </SUP>infection.<SUP><A HREF="#REF35">35</A></SUP> Interestingly, patient 20, with the 367G&gt;C mutation<SUP> </SUP>(resulting in skipping of exon 3 and production of a small amount<SUP> </SUP>of mutated [Lys96Asn] nonfunctional CD40L) developed PCP at<SUP> </SUP>4 months of age and subsequently suffered from recurrent sinopulmonary<SUP> </SUP>infections. Thus, a detailed analysis of the CD40L mutation<SUP> </SUP>and its effect on CD40L expression and function provides useful<SUP> </SUP>information that may affect prognostic and therapeutic decisions
Based on our current studies, we propose a model, shown in <A HREF="#FIG7">Figure 7</A>,<SUP> </SUP>for parvovirus B19 infection where binding of parvovirus<SUP> </SUP>B19 to RBCs, which only express the primary binding receptor,<SUP> </SUP>P antigen, can occur (<A HREF="#FIG7">Figure 7A</A>); however, viral entry is restricted<SUP> </SUP>to progenitor cells within the erythroid lineage, because these<SUP> </SUP>cells express high levels of P antigen as well as the coreceptor,<SUP> </SUP>activated <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin (<A HREF="#FIG7">Figure 7B</A>). Further studies are required<SUP> </SUP>to gain a better understanding of the underlying mechanism of<SUP> </SUP>viral transport within the blood circulation, transition into<SUP> </SUP>the bone marrow cavity, and mechanism of internalization into<SUP> </SUP>its target erythroid progenitor cell, which, in turn, will be<SUP> </SUP>useful in utilizing the <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin&#150;mediated target cell&#150;selective<SUP> </SUP>entry of parvovirus B19 using recombinant parvovirus B19 vectors<SUP> </SUP>in gene therapy in general and of parvovirus B19-globin vectors<SUP> </SUP>in gene therapy of human hemoglobinopathies in particular
Polyarteritis, either macroscopic or microscopic, is a rare
disease in childhood.<SUP><a href="#B19">19</A></SUP><SUP>,</SUP><SUP><a href="#B20">20</A></SUP> Polyarteritis nodosa has been
associated<SUP> </SUP>with HBV, human immunodeficiency virus, CMV, parvovirus B19,
human<SUP> </SUP>T-lymphotropic virus type I, and hepatitis C
virus.<SUP><a href="#B21">21</A></SUP> Chronic<SUP> </SUP>EBV infection has been associated with
large-vessel arteritis<SUP> </SUP>and Kawasaki-like arteritis,<SUP><a href="#B9">9</A></SUP><SUP>,</SUP><SUP><a href="#B10">10</A></SUP>
and the EBV genome has been<SUP> </SUP>detected in the diseased aortic tissue by
PCR.<SUP><a href="#B10">10</A></SUP><SUP>,</SUP><SUP><a href="#B22">22</A></SUP> In an animal<SUP> </SUP>model of vasculitis, infection of
mice with murine <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma ">-herpesvirus<SUP> </SUP>68&nbsp;caused a severe large-vessel
vasculitis with detectable viral<SUP> </SUP>antigen in the arteritic lesions and
in vascular smooth muscle.<SUP><a href="#B11">11</A></SUP><SUP> </SUP>Arteritis and chronic viral
infection occurred in interferon-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma "><SUP> </SUP>(IFN-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma ">) null or IFN-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma "> receptor
null mice demonstrating a role<SUP> </SUP>for IFN-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma "> in regulating chronic
<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma ">-herpesvirus infection. Arteritis<SUP> </SUP>also occurred in infected weanling
but not adult healthy mice.<SUP> </SUP>This demonstrates that <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma ">-herpesvirus 68,&nbsp;a virus related to EBV,<SUP> </SUP>has a tropism for smooth muscle, can induce
arteritis, and that<SUP> </SUP>IFN-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma "> is essential to control vascular infection
or resultant<SUP> </SUP>inflammation. EBV likewise may have tropism for smooth
muscle,<SUP> </SUP>as the EBV genome is detected within smooth muscle
tumors.<SUP><a href="#B23">23</A></SUP><SUP> </SUP>As we have shown the presence of EBV DNA in the
affected vascular<SUP> </SUP>structures of our patient, the murine model described
may parallel<SUP> </SUP>the pathophysiology of our<SUP> </SUP>case
PSS is a complicated autoimmune disease whose aetiology remains<SUP> </SUP>unknown and there is increasing evidence implicating the involvement<SUP> </SUP>of infectious agents, such as parvovirus B19 [<A HREF="#BIB1">1</A>, <A HREF="#BIB2">2</A>], in its<SUP> </SUP>pathogenesis. We present here a patient with scleroderma and<SUP> </SUP>possible concurrent infection with parvovirus B19 and Epstein&#150;Barr<SUP> </SUP>virus (EBV). Active parvovirus B19 and EBV infection were documented<SUP> </SUP>by positive IgM in serum by enzyme-linked immunosorbent assay<SUP> </SUP>and <I>in situ</I> hybridization in skin biopsy. On reviewing the literature,<SUP> </SUP>parvovirus B19 is shown to be able to establish latency in the<SUP> </SUP>bone marrow [<A HREF="#BIB3">3</A>], from where the virus could spread to target<SUP> </SUP>tissues, and significant elevation of the virus DNA in the skin<SUP> </SUP>of systemic sclerosis patients has been proved [<A HREF="#BIB4">4</A>]. To assume<SUP> </SUP>a cause and effect relationship between parvovirus B19 and scleroderma<SUP> </SUP>is an attractive concept; however, the demonstration of the<SUP> </SUP>viral DNA could be due to non-specific immune stimulation
Conclusion</STRONG><BR>

In conclusion, we report that circulating TNF-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> and IFN-<IMG SRC="/math/gamma.gif" ALT="{gamma}" BORDER="0"> levels<SUP> </SUP>are raised during acute and convalescent parvovirus B19 infection<SUP> </SUP>and are associated with prolonged and chronic fatigue. These<SUP> </SUP>findings shed new light on our knowledge of the host response<SUP> </SUP>to this infection, its chronicity in certain individuals and<SUP> </SUP>the pathogenesis of B19 virus-associated fatigue. As B19 virus<SUP> </SUP>infects most people worldwide, these findings suggest that cytokines<SUP> </SUP>produced during the years following acute infection in certain<SUP> </SUP>individuals may predispose to the development of other diseases<SUP> </SUP>and provide clues as to the mechanism of other observed phenomena,<SUP> </SUP>such as parvovirus-mediated oncosuppression
S<FONT SIZE=-1>IR</FONT>, Parvovirus B19 is an agent that causes several clinical<SUP> </SUP>manifestations, the most common being erythema infectiosum in<SUP> </SUP>children. It has also been associated with bone marrow suppression,<SUP> </SUP>most commonly transient red cell aplasia in patients with chronic<SUP> </SUP>haemolysis [<A HREF="#R1">1</A>]. Several reports have linked parvovirus with<SUP> </SUP>necrotizing vasculitis disorders [<A HREF="#R2">2</A>&#150;<A HREF="#R9">9</A>]. We report a unique<SUP> </SUP>case of a patient who developed vasculitis and myelosuppression<SUP> </SUP>simultaneously during the course of an acute parvovirus B19<SUP> </SUP>infection
PARVOVIRIDAE IS a large family of small animal viruses that have been isolated from many species, from insects to humans.<SUP><a href="#B1">1-3</A></SUP>  The H-1 virus used in the present study belongs to the subgroup of autonomously replicating parvoviruses of vertebrates and contains a single-stranded, linear DNA genome of about 5 kb.<SUP><a href="#B4">4-8</A></SUP>  The parvovirus life cycle depends on cellular factors that are expressed as a function of cell proliferation and differentiation.<SUP><a href="#B6">6</A></SUP>  In contrast to DNA tumor viruses, parvoviruses are unable to force quiescent infected cells into the S phase of the cell cycle. Cancer cells can be assumed to provide these viruses with an environment beneficial to their multiplication. Indeed, several parvoviruses appear to be oncotropic.<SUP><a href="#B9">9</A></SUP><SUP>,</SUP><SUP><a href="#B10">10</A></SUP>  In agreement with this, our previous studies have shown that in vitro transformation of various cell lines correlated with their sensitization to parvovirus-induced killing and with an increased capacity to sustain certain steps of the viral life-cycle as compared to their untransformed counterparts.<SUP><a href="#B11">11</A></SUP>  In particular, the production and the toxic activity of the nonstructural protein NS1, a key effector of parvovirus replication and cytopathogenicity, is stimulated in oncogene-transformed cells.<SUP><a href="#B12">12-14</A></SUP>  This modulation may account, at least in part, for the fact that parvoviruses are not only devoid of oncogenic activity, but can even exert an oncosuppressive effect in vivo.<SUP><a href="#B9">9</A></SUP>  The mechanism of this anticancer surveillance is poorly understood at present. To unravel the pathways of tumor suppression at the molecular level, H-1 virus was used for isolating from the human K562 erythroleukemic cell line rare variants (designated KS) that resisted virus infection.<SUP><a href="#B15">15</A></SUP>  These variants were distinguishable from the parental cells not only by their insensitivity to the cytopathic effect of H-1 virus, but also by a much reduced malignant phenotype correlating with the reactivation of wild-type (wt) p53 tumor suppressor gene expression. Furthermore, transformed rat embryo fibroblasts producing high levels of a p53 mutant protein, able to oligomerize and inactivate endogenous wt p53, were shown to be sensitized to H-1 virus infection.<SUP><a href="#B15">15</A></SUP>  Therefore, a close interconnection appears to exist between the commitment of cells to neoplastic transformation and their susceptibility to parvovirus infection
Rituximab is a chimeric monoclonal antibody directed
against CD20 and used in the treatment of B-cell non-Hodgkin's
lymphoma.<SUP> </SUP>Due to its ability to deplete B lymphocytes, rituximab can
interfere<SUP> </SUP>with humoral immunity, causing it to be suppressed for
several<SUP> </SUP>months after treatment. The reported case depicts a serious
consequence<SUP> </SUP>of this effect of rituximab therapy: pure red cell aplasia
resulting<SUP> </SUP>from chronic parvovirus B19 infection. The point of interest
in<SUP> </SUP>this case is not only the association between rituximab therapy<SUP> </SUP>and
pure red cell aplasia, but the diagnostic and therapeutic<SUP> </SUP>utility of
the knowledge of parvovirus B19 as the likely etiologic<SUP> </SUP>link between
the two. Given the known efficacy of intravenous<SUP> </SUP>immunoglobulin (IVIg)
in the treatment of chronic parvovirus B19<SUP> </SUP>infection, this therapy
can cure some of  these patients and successfully<SUP> </SUP>render most others
transfusion-independent  until recovery of their<SUP> </SUP>own humoral immune<SUP> </SUP>system.

(Blood. 2000;96:1184-1186)<BR>
<BR>
&#169; 2000 by The American Society of Hematology
IVIg has been found to be an effective therapy for chronic parvovirus
B19 infection. Commercial IVIg is known to contain IgG<SUP> </SUP>antibodies to
parvovirus B19, which can control and may even eradicate<SUP> </SUP>B19
infection.<SUP><a href="#B11">11-13</A></SUP> This therapy was successful in bringing
about<SUP> </SUP>a resolution of anemia in our patient. The detection of viral<SUP> </SUP>DNA
in circulation after clinical improvement following IVIg therapy<SUP> </SUP>merely
reflects the qualitative nature of the PCR test for B19,<SUP> </SUP>which is not
designed to accurately identify a quantitative drop<SUP> </SUP>in the viral load
reflected clinically by the increment in hemoglobin<SUP> </SUP>level. The test,
however, besides being highly sensitive, is also<SUP> </SUP>very specific, and a
positive result has been shown to predict<SUP> </SUP>true infection with great
accuracy, even in asymptomatic mass-screened<SUP> </SUP>blood
donors.<SUP><a href="#B14">14-16
HIV infection may lead to anemia in many ways: changes in cytokine
production with subsequent effects on hematopoiesis<SUP>7-9</SUP>;
decreased erythropoietin concentrations<SUP>10,11</SUP>; opportunistic
infectious agents, such as <I>Mycobacterium avium
</I>complex<SUP><a href="#B12">12</A></SUP> and parvovirus B-19<SUP>13</SUP>;
administration of chemotherapeutic agents such as
zidovudine,<SUP><a href="#B14">14</A></SUP> ganciclovir,<SUP><a href="#B15">15</A></SUP> and
trimethoprim-sulfamethoxazole<SUP>16</SUP>; and myelophthisis caused
by cancers such as lymphosarcoma. Other mechanisms for HIV-associated
anemia, although uncommon, include vitamin B<SUB>12</SUB>
deficiency<SUP><a href="#B17">17</A></SUP> and the autoimmune destruction of red blood
cells.<SUP><a href="#B18">18</A></SUP> Direct infection of marrow precursor
cells<SUP><a href="#B19">19</A></SUP> has been hypothesized, but not proven
Human parvovirus B19 infection is thought to be an infection<SUP> </SUP>transmitted most frequently by school-aged children. Our data<SUP> </SUP>support this observation because 47.0% of children younger than<SUP> </SUP>10 years of age were infected by the end of the observation<SUP> </SUP>period. This rate is higher than rates observed in healthy hosts<SUP> </SUP>from the United Kingdom and Australia where 27% to 28% are infected<SUP> </SUP>by 11 years of age.<SUP><A HREF="#REF21">21</A>,<A HREF="#REF22">22</A></SUP> Although the incidence and prevalence<SUP> </SUP>of HPV B19 infection in children with SCD in this study are<SUP> </SUP>high, they may be underestimated because of the lack of follow-up<SUP> </SUP>serologic tests in a small proportion of patients in this study


Our previous case of DM indicated a temporal association between<SUP> </SUP>parvovirus B19 infection and active myositis. Our present study<SUP> </SUP>and the published cases do not demonstrate the implication of<SUP> </SUP>parvovirus B19 in a particular phase of the disease or a subset<SUP> </SUP>of patients. If parvovirus B19 does contribute to the pathogenic<SUP> </SUP>process leading to myositis, it is probably through indirect<SUP> </SUP>mechanisms in patients with a particular genetic or risk factor


Although at first glance it would seem somewhat perplexing for<SUP> </SUP>parvovirus B19 to utilize a surface macromolecule as a coreceptor<SUP> </SUP>that is involved in cell adhesion, it is known that its target<SUP> </SUP>erythroid progenitor cell in the bone marrow exhibits an adherent<SUP> </SUP>phenotype at early stages of erythropoiesis that is mediated<SUP> </SUP>by the interaction of surface-expressed integrins of the <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 family<SUP> </SUP>with extracellular matrix fibronectin in the marrow microenvironment.<SUP><A HREF="#REF36">36</A></SUP><SUP> </SUP>The <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin&#150;mediated adhesion has been implicated in<SUP> </SUP>the regulation of progenitor anchoring, trafficking, proliferation,<SUP> </SUP>and differentiation.<SUP><A HREF="#REF37">37</A>,<A HREF="#REF38">38</A></SUP> At the stage of enucleating erythroblast/reticulocyte<SUP> </SUP>the <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins are lost from the cell surface and circulating<SUP> </SUP>RBCs do not express these receptors.<SUP><A HREF="#REF39">39</A></SUP> In addition, <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins,<SUP> </SUP>especially <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">4<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 and <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1, are expressed on human CD34<SUP>+</SUP> hematopoietic<SUP> </SUP>stem and progenitor and long-term culture-initiating cells (LTC-ICs)<SUP> </SUP>and are involved in fibronectin binding and transendothelial<SUP> </SUP>migration<SUP><A HREF="#REF40">40</A></SUP> as well as engraftment of human hematopoietic-repopulating<SUP> </SUP>cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID)<SUP> </SUP>mice.<SUP><A HREF="#REF41">41</A></SUP> Our data demonstrate that parvovirus B19 internalization<SUP> </SUP>into purified human erythroid progenitor cells can be completely<SUP> </SUP>inhibited by antibodies blocking <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin function, corroborating<SUP> </SUP>the notion that <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins play a crucial role in parvovirus<SUP> </SUP>B19 infection of its natural target cells
Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES. Pure red cell aplasia caused by parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant. 2000:14: 586-591.<!-- HIGHWIRE ID="106:8:2890:29" --><a href="/cgi/external_ref?access_num=10.1034/j.1399-0012.2000.140612.x&link_type=DOI" >[CrossRef]</a><A HREF="/cgi/external_ref?access_num=11127313&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=11127313&displayid=77140&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve
Ferri C, Zakrzewska K, Longombardo G <I>et al</I>. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999;17:718&#150;20.<!-- HIGHWIRE ID="44:10:1328:1" --><a href="/cgi/external_ref?access_num=000083659100012&link_type=ISI" >[ISI]</a><a href="/cgi/external_ref?access_num=10609071&link_type=MED" >[Medline]</a><!-- /HIGHWIRE --><A NAME="BIB2"><!-- null --></A>
<LI VALUE=2> Ferri C, Longombardo G, Azzi A, Zakrzewska K. Parvovirus B19 and systemic sclerosis. Clin Exp Rheumatol 1999;17:267&#150;8.<!-- HIGHWIRE ID="44:10:1328:2" --><a href="/cgi/external_ref?access_num=000079719800028&link_type=ISI" >[ISI]</a><a href="/cgi/external_ref?access_num=10342065&link_type=MED" >[Medline]</a><!-- /HIGHWIRE --><A NAME="BIB3"><!-- null --></A>
<LI VALUE=3> Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997;53:229&#150;32.<!-- HIGHWIRE ID="44:10:1328:3" --><a href="/cgi/external_ref?access_num=10.1002/(SICI)1096-9071(199711)53:3<229::AID-JMV8>3.3.CO;2-9&link_type=DOI" >[CrossRef]</a><a href="/cgi/external_ref?access_num=A1997YE75500008&link_type=ISI" >[ISI]</a><a href="/cgi/external_ref?access_num=9365887&link_type=MED" >[Medline]</a><!-- /HIGHWIRE --><A NAME="BIB4"><!-- null --></A>
<LI VALUE=4> Ohtsuka T, Yamazaki S. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 2004;150:1091&#150;5.<!-- HIGHWIRE ID="44:10:1328:4" --><a href="/cgi/external_ref?access_num=10.1111/j.0007-0963.2004.05930.x&link_type=DOI" >[CrossRef]</a><a href="/cgi/external_ref?access_num=000222685600005&link_type=ISI" >[ISI]</a><a href="/cgi/external_ref?access_num=15214893&link_type=MED" >[Medline]</a><!-- /HIGHWIRE --><A NAME="BIB5"><!-- null --></A>
<LI VALUE=5> Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248&#150;55.<!-- HIGHWIRE ID="44:10:1328:5" --><a href="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=345/4/248" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --></OL>



Accepted 27 May 2005
The patient, a male infant, first presented at 3&nbsp;weeks of age with
anemia, thrombocytopenia, leukocytosis (35-45&nbsp;&#215;&nbsp;10<SUP>9</SUP>
cells/L), and a "blueberry muffin" rash. He was delivered after<SUP> </SUP>a
full-term pregnancy, and his size was appropriate for gestational<SUP> </SUP>age.
There was no family history of recurrent infection, immune<SUP> </SUP>deficiency,
or consanguinity. Maternal screening was negative<SUP> </SUP>for infections,
including human immunodeficiency virus and hepatitis<SUP> </SUP>B.&nbsp;At the time of
presentation, assay of the infant's serum for<SUP> </SUP>IgM antibodies directed
against cytomegalovirus, rubella, toxoplasmosis,<SUP> </SUP>EBV, parvovirus, human
herpesvirus 6,&nbsp;and herpes simplex 1&nbsp;and<SUP> </SUP>2&nbsp;were all negative. Viral
cultures were also negative. In the<SUP> </SUP>fourth through seventh months of
life, he had several bacterial<SUP> </SUP>infections: an infected urachal duct
cyst (cultures grew <I>Bacteroides<SUP> </SUP>vulgaris</I>, <I>Enterococcus
faecalis</I>, <I>Enterococcus avium</I>, and <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">&nbsp;hemolytic<SUP> </SUP>streptococcus), pneumonia (<I>B vulgaris</I> and <I>Candida
albicans</I> were<SUP> </SUP>cultured from the bronchoalveolar lavage fluid),
nonhemolytic<SUP> </SUP>streptococcal septicemia, and a perirectal ulceration and
cellulitis<SUP> </SUP>without pus collection that grew <I>Escherichia coli</I>
on culture.<SUP> </SUP>He also had episodes of pneumonia caused by respiratory
syncitial<SUP> </SUP>and parainfluenza viruses, oral candidiasis, and a <I>C
albicans</I><SUP> </SUP>urinary tract infection, and pneumonia caused by
<I>Pneumocystis<SUP> </SUP>carinii</I>. The leukocytosis found at the time of
presentation persisted<SUP> </SUP>until bone marrow transplant, and leukocyte
counts as high as<SUP> </SUP>96&nbsp;&#215;&nbsp;10<SUP>9</SUP> cells/L were recorded.
Because the persistent leukocytosis and<SUP> </SUP>recurrent severe infections
suggested the possibility of LAD-1,<SUP> </SUP>analysis of cell surface
<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB> integrins on the infant's circulating<SUP> </SUP>neutrophils was
performed. Normal levels were detected (Table<SUP> </SUP><a href="#T1">1</a> and data not shown). Studies of
adhesive function of the child's<SUP> </SUP>circulating neutrophils were then
performed as described in detail<SUP> </SUP>below. A biopsy of the "blueberry
muffin" rash showed dermal erythropoiesis.<SUP> </SUP>At 6&nbsp;weeks of age, the
infant had normal quantitative IgG, IgA,<SUP> </SUP>and IgM levels. CD4 and CD8 T
lymphocyte numbers were normal.<SUP> </SUP>At 6&nbsp;months of age, the T-lymphocyte
function was assessed, and<SUP> </SUP>there were positive responses in vitro to
the mitogens phytohemagglutinin,<SUP> </SUP>concanavalin A, and pokeweed and to
specific antigens (tetanus<SUP> </SUP>and candida) after immunization and
infection, respectively
As stated above, parvoviruses have specific requirements for proliferating and usually poorly differentiated host cells. The human promonocytic leukemia cell line U937 fulfills these conditions and is very sensitive to H-1 virus infection. It was further reasoned that the uncoupling of cell growth and differentiation could be investigated by determining whether proliferating but H-1 virus-resistant U937 variant subclones could be isolated and, should that be the case, by characterizing their phenotypic traits. A marker of particular interest consisted of the p53 protein, given the key role of this protein in cell proliferation and differentiation<SUP><a href="#B28">28</A></SUP><SUP>,</SUP><SUP><a href="#B29">29</A></SUP>  and its reactivation in H-1 virus-resistant KS variants of human erythroleukemic cells.<SUP><a href="#B15">15</A></SUP>  Our results show that growing U937 subclones that resist H-1 virus infection (designated RU) can indeed be found. The RU subclones analyzed differ from KS cells by the lack of a detectable change in p53 status compared with the respective H-1 virus-sensitive parental lines, pointing to the fact that multiple pathways may lead to parvovirus resistance. RU cells exhibit a unique activated phenotype including the constitutive production of active oxygen species. Altogether, these data uncover a novel mechanism by which cells may become resistant to parvovirus infection, and identify specific monocytic differentiation traits that can be uncoupled from cell proliferation arrest
Untreated, PMA-treated K562 cells (2 <FONT FACE="arial,helvetica">x</FONT> 10<SUP>6</SUP>), or primary human<SUP> </SUP>erythroid progenitor cells (1 <FONT FACE="arial,helvetica">x</FONT> 10<SUP>6</SUP>) were washed twice with<SUP> </SUP>IMDM supplemented with 1 mM Mg<SUP>2+</SUP> and 1 mM Mn<SUP>2+</SUP>, preincubated<SUP> </SUP>first with 20 &#181;g/mL normal mouse IgG for 10 minutes at<SUP> </SUP>room temperature to block Fc receptors, and subsequently with<SUP> </SUP>25 &#181;g/mL or 50 &#181;g/mL activating (N29) or inhibitory<SUP> </SUP>(P4C10) <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin antibodies for 30 minutes at room temperature.<SUP> </SUP>A total of 10 &#181;L (for infection of K562 cells) or 5 &#181;L<SUP> </SUP>(for infection of CD71<SUP>+</SUP> cells) of serum containing 10<SUP>9</SUP> and 5<SUP> </SUP><FONT FACE="arial,helvetica">x</FONT> 10<SUP>8</SUP> wild-type parvovirus B19 particles, respectively, were<SUP> </SUP>either untreated or preincubated with 10 &#181;g and 5 &#181;g<SUP> </SUP>antiparvovirus B19 VP2 monoclonal antibodies for 1 hour on ice.<SUP> </SUP>Cells were infected for 1 hour at 37&#176;C, washed, and uninternalized<SUP> </SUP>viral particles were removed by trypsinization (0.05% trypsin<SUP> </SUP>plus 0.02% EDTA at 37&#176;C for 5 minutes) as described previously.<SUP><A HREF="#REF17">17</A></SUP><SUP> </SUP>Low <I>M</I><SUB>r</SUB> DNA was isolated and analyzed on Southern blots using<SUP> </SUP>a parvovirus B19<B>-</B>specific DNA probe
View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/41/10/1210/T1">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/41/10/1210/T1"
    onClick="startTarget('T1', 500, 400); this.href='/cgi/content-nw/full/41/10/1210/T1'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T1">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
T<FONT SIZE=-1>ABLE</FONT> 1. Clinical features, means of diagnosis and treatment leading to resolution of symptoms in reported cases of necrotizing vasculitis and parvovirus infection


Introduction 
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Methods<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Feline panleukopenia virus (FPV) and canine parvovirus (CPV-2)<SUP> </SUP>are significant pathogens for domestic cats and dogs as well<SUP> </SUP>as for various wild carnivore species. CPV-2 and FPV are very<SUP> </SUP>closely related viruses, showing a genome homology of 98%, and<SUP> </SUP>are grouped along with other viruses such as mink enteritis<SUP> </SUP>virus (MEV), raccoon parvovirus (RPV), raccoon dog parvovirus<SUP> </SUP>(RDPV) and blue fox parvovirus (BFPV) in the so-called feline<SUP> </SUP>parvovirus subgroup. FPV-induced disease in cats has been known<SUP> </SUP>since the beginning of the 20th century (Verge <I>et al</I>., 1928<A HREF="#R26"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>) whereas CPV-2 and its associated disease in dogs emerged suddenly<SUP> </SUP>in the late 1970s (Appel <I>et al</I>., 1978<A HREF="#R2"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). CPV-2 spread globally<SUP> </SUP>within a few months, initially killing thousands of unprotected<SUP> </SUP>dogs worldwide; the new virus most likely had its origin in<SUP> </SUP>an FPV-like virus but the mechanism of its evolution is still<SUP> </SUP>unknown (Parrish, 1990<A HREF="#R11"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). These two closely related viruses<SUP> </SUP>differ antigenically and in their host ranges. FPV replicates<SUP> </SUP>only in feline cells <I>in vitro</I> and in cats <I>in vivo</I> whereas CPV-2<SUP> </SUP>replicates in canine and feline cells <I>in vitro</I>, but does not<SUP> </SUP>infect cats <I>in vivo</I> (Truyen <I>et al</I>., 1992<A HREF="#R18"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The host range difference<SUP> </SUP>between FPV and CPV-2 is determined by six coding nucleotides<SUP> </SUP>(positions 3025, 3065, 3094, 3753, 4477 and 4498; Fig. 1<A HREF="#F1"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A>) in<SUP> </SUP>the right open reading frame (ORF) encoding structural proteins<SUP> </SUP>VP1 and VP2. These amino acid changes had subsequent effects<SUP> </SUP>on the viral surface structure which facilitated replication<SUP> </SUP>in canine cells but also led to loss of the feline host range<SUP> </SUP>(Truyen <I>et al</I>., 1996<I>a</I><A HREF="#R21"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). Soon after the appearance of CPV-2<SUP> </SUP>new antigenic types, termed CPV-2a and CPV-2b, emerged (Parrish<SUP> </SUP><I>et al</I>., 1991<A HREF="#R13"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> <I>a</I>) and replaced the original CPV-2 worldwide (Parrish<SUP> </SUP><I>et al</I>., 1991<A HREF="#R13"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> <I>a</I>; Truyen <I>et al</I>., 1996<I>b</I><A HREF="#R22"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Steinel <I>et al</I>., 1998<A HREF="#R16"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>). These new types differ from the original CPV-2 by additional<SUP> </SUP>nucleotide changes at positions 3045, 3685, 3699, 4062 and 4449<SUP> </SUP>(Fig. 1<A HREF="#F1"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A>) and by their extended host range, now including dog<SUP> </SUP>and cat (Truyen <I>et al</I>., 1996<I>a</I><A HREF="#R21"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Mochizuki <I>et al</I>., 1996<A HREF="#R10"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). In<SUP> </SUP>Germany and the United States about 5% of the cases of feline<SUP> </SUP>parvovirus infections in domestic cats are caused by CPV-2a<SUP> </SUP>or CPV-2b (Truyen <I>et al</I>., 1996<I>b
Five unrelated patients, all teenagers or young adults, had phenotypes
that clearly distinguished them from patients with<SUP> </SUP>classic XHIM
(Table <a href="#T4">4</a>). Two had identical missense
mutations<SUP> </SUP>affecting exon 5&nbsp;(T254M), one had a nonsense mutation (R11X),<SUP> </SUP>and two had splice site mutations affecting intron 2&nbsp;(nt 309&nbsp;+<SUP> </SUP>2t
<IMG SRC="/math/12pt/normal/rarr.gif" ALIGN=BASELINE ALT="right-arrow">&nbsp;a) and exon 3&nbsp;(nt 367G <IMG SRC="/math/12pt/normal/rarr.gif" ALIGN=BASELINE ALT="right-arrow">&nbsp;A), respectively. All were
older<SUP> </SUP>at onset, never had PCP, and neutropenia was observed in only<SUP> </SUP>two
cases, one intermittently and one during parvovirus B19 infection.<SUP> </SUP>Parvovirus B19-induced red blood cell aplasia was the presenting<SUP> </SUP>illness in three of the five patients with a mild phenotype, but<SUP> </SUP>was
not observed in patients with classic XHIM. In the latter<SUP> </SUP>group of
patients, Ig therapy was started at a mean age of 1.5<SUP> </SUP>years. In the
five patients with mild disease, IVIg therapy was<SUP> </SUP>started much later.
None of the patients presenting with parvovirus<SUP> </SUP>B19-induced anemia had
received IVIg prophylaxis at the time they<SUP> </SUP>developed symptoms, and at
present only three of our patients<SUP> </SUP>with a milder phenotype receive
regular IVIg infusions. It is<SUP> </SUP>conceivable that patients with classic
XHIM avoid infection with<SUP> </SUP>parvovirus B19 because they are recognized
earlier and started<SUP> </SUP>on IVIg at a younger age than those XHIM patients
with a milder<SUP> </SUP>phenotype. Of those with mild disease, none had any
problems with<SUP> </SUP>recurrent infections regardless of treatment with IVIg.
Activated<SUP> </SUP>T-cell lines from patients with a mild phenotype were able to<SUP> </SUP>bind all four anti-CD40L MoAbs tested (immunostaining type 2)<SUP> </SUP>and three
could bind CD40-Ig (immunostaining type 1); in contrast,<SUP> </SUP>activated
T-cell lines from most patients (80%) with a classic<SUP> </SUP>XHIM phenotype
were classified as immunostaining type 3,&nbsp;4,&nbsp;or<SUP> </SUP>5&nbsp;and did not bind
CD40-Ig
Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Materials and methods<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Giant cell arteritis (GCA) is a disease characterized by acute<SUP> </SUP>inflammation in medium to large arteries in elderly people.<SUP> </SUP>The disease has a predilection for branches of the temporal<SUP> </SUP>arteries. Typically, panarteritis is seen with granulomas composed<SUP> </SUP>of T cells, activated macrophages and multinucleated giant cells.<SUP> </SUP>The cause of GCA is unknown. Great variation in the incidence<SUP> </SUP>of GCA has been reported in different parts of the world, with<SUP> </SUP>a high incidence in Scandinavia [<A HREF="#R1">1</A>], suggesting that environmental<SUP> </SUP>or genetic factors may contribute to the pathogenesis. Although<SUP> </SUP>certain <I>HLA-DR</I> alleles are correlated with GCA [<A HREF="#R2">2</A>], genetic<SUP> </SUP>factors are insufficient to explain the marked variation in<SUP> </SUP>geographic prevalence and the temporal fluctuation in the incidence<SUP> </SUP>of the disease. Regular cyclical patterns in the incidence rate<SUP> </SUP>of GCA over time were shown in Minnesota, with a peak every<SUP> </SUP>6&#150;7 yr [<A HREF="#R3">3</A>]. Similarly, a Danish study reported cyclic<SUP> </SUP>fluctuations that coincided with epidemics of <I>Mycoplasma pneumoniae</I>,<SUP> </SUP>parvovirus B19 and <I>Chlamydia pneumoniae</I> [<A HREF="#R4">4</A>]. Furthermore, a<SUP> </SUP>retrospective study of 100 patients with GCA found that the<SUP> </SUP>prevalence of recent or current infections in patients with<SUP> </SUP>temporal arteritis was three times higher than that in matched<SUP> </SUP>control patients [<A HREF="#R5">5</A>]. These findings suggest that infectious<SUP> </SUP>agents may be involved in the pathogenesis of the disease. Recently,<SUP> </SUP>possible associations between GCA and infection with parvovirus<SUP> </SUP>B19 or <I>C. pneumoniae</I> have been reported [<A HREF="#R6">6</A>, <A HREF="#R7">7</A>]. In the present<SUP> </SUP>study we searched for evidence of these infections as well as<SUP> </SUP>infection with the human herpes viruses by using the polymerase<SUP> </SUP>reaction (PCR) on temporal artery biopsies obtained prospectively<SUP> </SUP>from patients suspected of having GCA
Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Introduction<BR></A>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Methods<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


Infections with viruses of the feline parvovirus subgroup such<SUP> </SUP>as feline panleukopenia virus (FPV), mink enteritis virus (MEV)<SUP> </SUP>and canine parvovirus (CPV-2) [together with its new antigenic<SUP> </SUP>types (CPV-2a, CPV-2b)] have been reported from several wild<SUP> </SUP>carnivore species. To examine the susceptibility of different<SUP> </SUP>species to the various parvoviruses and their antigenic types,<SUP> </SUP>samples from wild carnivores with acute parvovirus infections<SUP> </SUP>were collected. Viral DNA was amplified, and subsequently analysed,<SUP> </SUP>from faeces or formalin-fixed small intestines from an orphaned<SUP> </SUP>bat-eared fox (<I>Otocyon megalotis</I>), a free-ranging honey badger<SUP> </SUP>(<I>Mellivora capensis</I>), six captive cheetahs (<I>Acinonyx jubatus</I>),<SUP> </SUP>a captive Siberian tiger (<I>Panthera tigris altaica</I>) and a free-ranging<SUP> </SUP>African wild cat (<I>Felis lybica</I>). Parvovirus infection in bat-eared<SUP> </SUP>fox and honey badger was demonstrated for the first time. FPV-sequences<SUP> </SUP>were detected in tissues of the African wild cat and in faeces<SUP> </SUP>of one cheetah and the honey badger, whereas CPV-2b sequences<SUP> </SUP>were found in five cheetahs and the bat-eared fox. The Siberian<SUP> </SUP>tiger (from a German zoo) was infected with a CPV-type 2a virus.<SUP> </SUP>This distribution of feline parvovirus antigenic types in captive<SUP> </SUP>large cats suggests an interspecies transmission from domestic<SUP> </SUP>dogs. CPV-2 sequences were not detected in any of the specimens<SUP> </SUP>and no sequences with features intermediate between FPV and<SUP> </SUP>CPV were found in any of the animals examined
Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Introduction<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Patients, materials, and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


Human parvovirus (HPV) B19 causes significant morbidity and<SUP> </SUP>mortality in children with sickle cell disease (SCD), but little<SUP> </SUP>data are published about the epidemiology of HPV B19 infection<SUP> </SUP>and its associated complications in this patient population.<SUP> </SUP>In this study, prevalence and incidence rates of HPV B19 were<SUP> </SUP>determined in 633 patients with SCD followed at The Children's<SUP> </SUP>Hospital of Philadelphia between November 1996 and December<SUP> </SUP>2001. Thirty percent (30%) were HPV B19 immunoglobulin G (IgG)<SUP> </SUP>positive at first testing, and the 70% without evidence of past<SUP> </SUP>HPV B19 infection were tested annually. One hundred ten patients<SUP> </SUP>developed evidence of HPV B19 infection for an incidence rate<SUP> </SUP>of 11.3 per 100 patientyears. Sixty-eight episodes of HPV B19&#150;induced<SUP> </SUP>transient red cell aplasia occurred with the following clinical<SUP> </SUP>events: fever (89.7%), pain (61.8%), acute splenic sequestration<SUP> </SUP>(19.1%), and acute chest syndrome (11.8%). Pain, fever, and<SUP> </SUP>acute splenic sequestration were more frequent events with acute<SUP> </SUP>HPV B19 infections compared with acute events in uninfected<SUP> </SUP>patients. The results of this epidemiologic study, the largest<SUP> </SUP>and most comprehensive to date, justify the development of HPV<SUP> </SUP>B19 prevention strategies to diminish the frequent and often<SUP> </SUP>severe complications associated with HPV B19 infections in patients<SUP> </SUP>with SCD
Thrombocytopenia is common in dengue fever and is constant in<SUP> </SUP>DHF/DSS (Bhamarapravati, 1989<A HREF="#R2"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Henchal &amp; Putnak, 1990<A HREF="#R9"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ).<SUP> </SUP>The pathogenesis of thrombocytopenia is poorly understood. La<SUP> </SUP>Russa &amp; Innis (1995)<A HREF="#R12"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A>  suggested that dengue virus-induced<SUP> </SUP>bone marrow suppression depressed platelet synthesis and resulted<SUP> </SUP>in thrombocytopenia. Wang <I>et al.</I> (1995)<A HREF="#R25"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A>  found that dengue-2<SUP> </SUP>virus can bind to human platelets in the presence of virus-specific<SUP> </SUP>antibody and proposed that the immune-mediated clearance of<SUP> </SUP>platelets was involved in the pathogenesis of thrombocytopenia<SUP> </SUP>in DHF/DSS. Parvovirus infection is associated with childhood<SUP> </SUP>idiopathic thrombocytopenic purpura (Yoto <I>et al.</I>, 1993<A HREF="#R27"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Heegaard<SUP> </SUP><I>et al.</I>, 1999<A HREF="#R8"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). To our knowledge, this study is the first to<SUP> </SUP>report the generation of anti-platelet antibody after dengue-2<SUP> </SUP>virus infection and to describe the association between anti-dengue<SUP> </SUP>virus immune response and its cross-reactivity to platelets.<SUP> </SUP>The anti-platelet antibody will lyse platelets in the presence<SUP> </SUP>of complement. It also interferes with thrombin-induced platelet<SUP> </SUP>aggregation (unpublished observation). Recently, we also found<SUP> </SUP>the presence of anti-platelet auto-antibody in the sera of dengue<SUP> </SUP>patients, and its level was higher in DHF/DSS patients than<SUP> </SUP>in dengue fever patients (unpublished data). Further studies<SUP> </SUP>are needed to clarify the relationship between dengue virus<SUP> </SUP>infection and autoimmunity


Cohen B. Parvovirus B19; an expanding spectrum of disease. BMJ1995; 311: S1549&#150;1552<!-- HIGHWIRE ID="15:9:1486:1" --><!-- /HIGHWIRE -->
<A NAME="R2"><!-- null --></A>
<LI VALUE=2>
 Lai MK. Viral hepatitis and kidney transplantation. J Formos Med Assoc1998; 97: 801&#150;811<!-- HIGHWIRE ID="15:9:1486:2" --><A HREF="/cgi/external_ref?access_num=000077813000001&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9884481&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R3"><!-- null --></A>
<LI VALUE=3>
 Pardi DS, Romero Y, Mertz LE <I>et al</I>. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol1998; 93: 468&#150;470<!-- HIGHWIRE ID="15:9:1486:3" --><A HREF="/cgi/external_ref?access_num=000073194100047&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9517662&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R4"><!-- null --></A>
<LI VALUE=4>
 Kurtzman GJ, Cohen BJ, Field AM, <I>et al</I>. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest1989; 84: 1114&#150;1123<!-- HIGHWIRE ID="15:9:1486:4" --><A HREF="/cgi/external_ref?access_num=A1989AT80800010&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=2551923&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->
<A NAME="R5"><!-- null --></A>
<LI VALUE=5>
 Lee PC, Wang YW, Su IJ <I>et al</I>. Immunosuppressive drugs and HHV-8 in a patient with a renal transplant and Kaposi's sarcoma. Lancet1998; 351: 1175&#150;1176<!-- HIGHWIRE ID="15:9:1486:5" --><A HREF="/cgi/external_ref?access_num=000073220200013&link_type=ISI" >[ISI]</A><A HREF="/cgi/external_ref?access_num=9643691&link_type=MED" >[Medline


Three different species of the family <I>Felidae</I> were examined:<SUP> </SUP>one African wild cat, six cheetahs and one Siberian tiger. The<SUP> </SUP>African wild cat, belonging to the genus <I>Felis</I>, is one of the<SUP> </SUP>closest relatives of the domestic cat (<I>Felis catus</I>; Wayne <I>et<SUP> </SUP>al</I>., 1989<A HREF="#R28"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The domestic cat is a host for CPV-2a and CPV-2b<SUP> </SUP>as well as for FPV but the main cause of parvoviral infection<SUP> </SUP>in domestic cats remains FPV, with an incidence of 95% (Truyen<SUP> </SUP><I>et al</I>., 1996<I>b</I><A HREF="#R22"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The African wild cat examined was infected<SUP> </SUP>with FPV, but in this study CPV-2a and CPV-2b seem to be the<SUP> </SUP>predominant infectious agents in large cats. FPV was found only<SUP> </SUP>in one cheetah from Namibia whereas the other five cheetahs<SUP> </SUP>from Namibia and the United States were infected with a CPV-2b<SUP> </SUP>virus. Also, the sequences obtained from the Siberian tiger<SUP> </SUP>were from a CPV-2a-like virus. The reason for the much higher<SUP> </SUP>incidence of CPV-2a/2b infections in large cats compared to<SUP> </SUP>domestic cats is unknown. Perhaps they are more susceptible<SUP> </SUP>to canine parvovirus infection, reminiscent of the higher susceptibility<SUP> </SUP>of large cats to canine distemper virus (Roelke-Parker <I>et al</I>.,<SUP> </SUP>1996<A HREF="#R14"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ). The high incidence of CPV-2a/2b in large cats has to<SUP> </SUP>be considered especially when dealing with valuable and endangered<SUP> </SUP>species, such as cheetahs and tigers. At places with high, unavoidable<SUP> </SUP>parvovirus contamination such as veterinary clinics, zoos or<SUP> </SUP>animal orphanages, the risk of infection is high for unprotected<SUP> </SUP>animals. In zoological gardens, virus carriers such as stray<SUP> </SUP>cats, visitors&#146; dogs, martens or others may play a role<SUP> </SUP>in contaminating the environment with the highly resistant feline<SUP> </SUP>parvoviruses. The source of infection for the large cats is<SUP> </SUP>unknown; however, it appears likely that they acquire the virus<SUP> </SUP>from dogs, as CPV-2a and CPV-2b are the prevalent viruses in<SUP> </SUP>dog populations. The parvoviruses obtained from the cheetah<SUP> </SUP>samples analysed from the United States and Namibia were all<SUP> </SUP>CPV-2b viruses, which is consistent with the fact that 70&#150;90%<SUP> </SUP>of all canine parvoviruses isolated from dogs in these countries<SUP> </SUP>are CPV-2b viruses (Parrish <I>et al</I>., 1991<A HREF="#R13"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A> ; Steinel <I>et al</I>., 1998<A HREF="#R16"><IMG BORDER=1 WIDTH=8 HEIGHT=7 SRC="/icons/fig-down.gif"></A><SUP> </SUP>). In contrast, the Siberian tiger from Germany was infected<SUP> </SUP>with a CPV-2a virus, which correlates with the predominance<SUP> </SUP>of this virus type in Germany (Truyen <I>et al</I>., 1996<I>b
Abstract
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Abstract</FONT><BR>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Case report<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>


We report a case of dermatomyositis associated with molecular<SUP> </SUP>evidence of parvovirus B19 DNA in two muscle biopsies collected<SUP> </SUP>5 months apart. IgG- but not IgM-specific antibodies were detected<SUP> </SUP>in serum. None of four serum samples was positive for parvovirus<SUP> </SUP>B19 DNA. The two biopsies contained B19 VP1 sequences and the<SUP> </SUP>second one was also positive for NS1. This is the first report<SUP> </SUP>of viral parvovirus B19 DNA in muscle of a patient with dermatomyositis.<SUP> </SUP>Latent muscle infection may contribute to the clinical picture
Environmental risk factors
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<A  HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Background<BR></A>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">The Norfolk Arthritis Register<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Assessment of patients referred...<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">The NOAR case-control study<BR></A>
<A  HREF="#SEC5"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Genetic risk factors<BR></A>
<A  HREF="#SEC6"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Hormonal and reproductive risk...<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Environmental risk factors</FONT><BR>
<A  HREF="#SEC8"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Conclusion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

<STRONG>Medical risk factors</STRONG><BR>

Infectious agents have been suspected as potential triggers<SUP> </SUP>of RA for a long time. However, no organisms have been recovered<SUP> </SUP>consistently from synovial tissue or fluid, and serological<SUP> </SUP>studies for a wide variety of bacteria, mycobacteria, viruses<SUP> </SUP>and parasites have been negative when applied to cohorts of<SUP> </SUP>patients with recent-onset RA. In the NOAR patients there was<SUP> </SUP>no evidence of clustering of RA in space or time [<A HREF="#R55">55</A>]. In the<SUP> </SUP>NOAR case&#150;control study the cases did not report an increased<SUP> </SUP>frequency of infections before the development of their arthritis<SUP> </SUP>[<A HREF="#R5">5</A>]. This suggests that RA is not caused by a single organism.<SUP> </SUP>It does not, however, rule out the possibility that infection<SUP> </SUP>may trigger RA in individual cases. It has been suggested that<SUP> </SUP>Epstein&#150;Barr virus [<A HREF="#R56">56</A>] and <I>Proteus</I> infection [<A HREF="#R57">57</A>] may<SUP> </SUP>play an aetiological role in some individuals, although results<SUP> </SUP>of different studies are conflicting. There are certainly well-documented<SUP> </SUP>cases of typical RA developing after proven infection with,<SUP> </SUP>for example, parvovirus and rubella [<A HREF="#R58">58</A>, <A HREF="#R59">59</A>]. Such cases do<SUP> </SUP>not make up a large proportion of all cases of RA but do, nevertheless,<SUP> </SUP>exist. In the NOAR cohort, only four out of 147 (2.7%) newly<SUP> </SUP>ascertained patients with a history of IP of less than 16 weeks<SUP> </SUP>tested positive for parvovirus. Three of the four patients satisfied<SUP> </SUP>the ACR criteria for RA [<A HREF="#R60">60
Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH
ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A  HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Patients, materials, and methods<BR></A>
<A  HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A  HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

Human parvovirus (HPV) B19, a common childhood infection, frequently<SUP> </SUP>causes transient red cell aplasia (TRCA) in children with sickle<SUP> </SUP>cell disease (SCD).<SUP><A HREF="#REF1">1</A>-<A HREF="#REF3">3</A></SUP> Although the outcome of some TRCA episodes<SUP> </SUP>in children with SCD is benign, many are treated with red cell<SUP> </SUP>transfusions to reduce the risk of circulatory collapse from<SUP> </SUP>severe anemia.<SUP><A HREF="#REF1">1</A>,<A HREF="#REF2">2</A></SUP> Furthermore, other HPV B19&#150;related complications,<SUP> </SUP>including acute splenic sequestration (ASS),<SUP><A HREF="#REF4">4</A></SUP> hepatic sequestration,<SUP><A HREF="#REF5">5</A>,<A HREF="#REF6">6</A></SUP><SUP> </SUP>acute chest syndrome (ACS),<SUP><A HREF="#REF7">7</A>,<A HREF="#REF8">8</A></SUP> nephrotic syndrome,<SUP><A HREF="#REF9">9</A>,<A HREF="#REF10">10</A></SUP> meningoencephalitis,<SUP> </SUP>and stroke,<SUP><A HREF="#REF11">11</A></SUP> also may occur. These complications or untreated<SUP> </SUP>severe anemia could result in chronic medical conditions or<SUP> </SUP>death.<SUP><A HREF="#REF1">1</A>,<A HREF="#REF7">7</A>,<A HREF="#REF12">12</A>,<A HREF="#REF13">13</A></SUP> Since HPV B19 was found to be the cause of TRCA<SUP> </SUP>in 1981,<SUP><A HREF="#REF14">14</A>,<A HREF="#REF15">15</A></SUP> clinicians have been eagerly awaiting the development<SUP> </SUP>of a vaccine or other prevention strategies that would diminish<SUP> </SUP>the morbidity and mortality of these infections.<SUP><A HREF="#REF16">16</A></SUP> Accurate<SUP> </SUP>epidemiologic data on the frequency of HPV B19 infection and<SUP> </SUP>its associated complications in children with SCD are essential<SUP> </SUP>for assessing the potential effect of viral prevention programs<SUP> </SUP>in this patient population
So far, the observation that parvovirus B19 and <I>C. pneumoniae</I><SUP> </SUP>infections are risk factors for GCA is based on only a few investigations.<SUP> </SUP>Our results do not confirm the findings of associations between<SUP> </SUP>these agents and GCA. In addition, we found no association between<SUP> </SUP>GCA and human herpes virus infection. To our knowledge, this<SUP> </SUP>study is the first to investigate temporal arteries for all<SUP> </SUP>eight human herpes viruses. Previously, only VZV has been investigated<SUP> </SUP>for a possible connection with GCA [<A HREF="#R28">28</A>]. Further studies are<SUP> </SUP>required to establish whether microbial infection is central<SUP> </SUP>to the aetiology of GCA


View larger version</STRONG> (73K):<BR>
<NOBR><A HREF="/cgi/content/full/102/12/3927/FIG2">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/102/12/3927/FIG2"
    onClick="startTarget('FIG2', 590, 500); this.href='/cgi/content-nw/full/102/12/3927/FIG2'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="FIG2">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 2.</B> <B>Activated cell surface <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins (<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1) mediate recombinant parvovirus B19 entry independent of fibronectin binding.</B> (A) Parvovirus B19 entry and nuclear localization in PMA-treated K562 cells were inhibited by inhibitory (P4C10) and increased by high-affinity conformation-stabilizing (N29, 21C8) <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin antibodies. K562 cells were infected with Cy3-labeled recombinant parvovirus B19 for 30 minutes, fixed, and nuclei stained with SYTO 16 green fluorescent nucleic acid stain. Original magnification, <FONT FACE="arial,helvetica">x</FONT> 630 for all panels. (B) Transduction of PMA-treated K562 cells with recombinant parvovirus B19-Luc vectors was inhibited by inhibitory <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5 and <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin antibodies (<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5, JB1a) but was independent of disruption of <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin interaction with fibronectin by RGD peptides (RGD). <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin activation induced either by stabilization of high-affinity <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins (N29) or by cross-linking of antibody-ligated <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins with goat antimouse secondary antibodies (JB1a+sec. Ab) resulted in an increase in transduction, whereas ligand binding without cross-linking (RGD+sec. Ab) had no effect. Data are representative of 3 independent experiments; error bars represent standard deviations (SDs). Firefly luciferase activity was detected in cell extracts 24 hours after infection as described in "Materials and methods." <SUP>*</SUP><I>P</I> &lt; .05; <SUP>**</SUP><I>P</I> &lt; .001
Another distinct feature of RU clones, compared with the parental U937 line, consists of their activation steady-state, ie, their constitutive capacity for producing oxygen metabolites, in particular O<SUP>-</SUP><SUB>2<SUP>.</SUP></SUB> and NO. This raised the question of the possible relevance of activation to the resistance of RU clones to H-1 virus. Indeed, oxidative responses were reported to play a protective role against some viral infections.<SUP><a href="#B52">52-55</A></SUP><SUP>,</SUP><SUP><a href="#B63">63</A></SUP><SUP>,</SUP><SUP><a href="#B64">64</A></SUP>  NO is a free radical gaseous molecule that can mediate vital physiologic functions, including host defense mechanisms.<SUP><a href="#B47">47</A></SUP>  Its interaction with superoxide anion yields the highly toxic peroxynitrite ONOO<SUP>-</SUP>. Implications of NO in antiviral activities were recently discovered.<SUP><a href="#B52">52-55</A></SUP>  Inhibition of NO synthesis in mice leads ectromelia virus to cause fulminant mousepox.<SUP><a href="#B53">53</A></SUP>  In addition, epithelial cells that fail to sustain a detectable NO synthesis become resistant to this virus when treated with organic compounds that generate NO. On the other hand, the replication of herpes simplex type 1 in murine macrophage-like RAW264.7 cells is drastically reduced after NO induction by IFN-<IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma ">.<SUP><a href="#B54">54</A></SUP>  To test whether the resistance of RU clones to H-1 virus may be related to the constitutive production of O<SUP>-</SUP><SUB>2<SUP>.</SUP></SUB> and/or NO, infected cells were incubated with compounds that scavenge these metabolites or inhibit their formation. Antioxidative treatments were found to sensitize RU cells to parvovirus toxicity and to increase the yields of infectious virus that can be procured from infected cultures. Because these yields are still very low compared with the H-1 virus burst released by permissive U937 cells, it is presently unclear whether antioxidants allow either a genuine virus production in RU cultures, or the recovery of a greater fraction of the inoculum due to the stabilization of incoming particles. Irrespective of whether parvovirus infection becomes productive or not, the cytopathic effect of H-1 virus on RU cells appears to be enhanced under antioxidative conditions. Although side effects of the O<SUP>-</SUP><SUB><B>2</B><SUP><B>.</B></SUP></SUB>/NO inhibitors used cannot be ruled out, these results raise the possibility that the activation steady-state may confer on RU cells some protection against parvovirus infection. A major restriction to the life cycle of H-1 virus in RU cells takes place at the level of viral gene expression. Further studies are required to determine how oxygen metabolites may interfere with this step of parvovirus replication
To directly examine the role of <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin in internalization<SUP> </SUP>of the wt parvovirus B19 into primary human erythroid progenitor<SUP> </SUP>cells, we used highly purified (more than 99% purity as determined<SUP> </SUP>by flow cytometry) CD71<SUP>+</SUP> early erythroid progenitor cells derived<SUP> </SUP>from human bone marrow. Flow cytometric analyses, shown in <A HREF="#FIG6">Figure 6A</A>,<SUP> </SUP>confirmed high-level expression of P antigen (<A HREF="#FIG6">Figure 6A</A>,<SUP> </SUP>left) as well as <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5 (<A HREF="#FIG6">Figure 6A</A>, middle) and <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 (<A HREF="#FIG6">Figure 6A</A>, right)<SUP> </SUP>integrins on these cells. Southern blot analysis, shown in <A HREF="#FIG6">Figure 6B</A>,<SUP> </SUP>indicated that whereas no signal was detected in uninfected<SUP> </SUP>erythroid progenitor cells (<A HREF="#FIG6">Figure 6B</A>, lane 1), the single-stranded<SUP> </SUP>wt parvovirus B19 genomes were readily detected in untreated<SUP> </SUP>cells (<A HREF="#FIG6">Figure 6B</A>, lane 2). Pretreatment of cells with inhibitory<SUP> </SUP><IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin antibody (P4C10) (<A HREF="#FIG6">Figure 6B</A>, lane 3) or pretreatment<SUP> </SUP>of wt parvovirus B19 with parvovirus B19 anti-VP2 antibodies<SUP> </SUP>(lane 5) abolished viral internalization. Preincubation of cells<SUP> </SUP>with inhibitory <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin antibodies and secondary goat antimouse<SUP> </SUP>IgG antibodies (JB1a+sec. Ab) did not affect parvovirus B19<SUP> </SUP>internalization (<A HREF="#FIG6">Figure 6B</A>, lane 4), suggesting that most <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1<SUP> </SUP>integrins expressed on primary erythroid progenitor cells are<SUP> </SUP>in a functionally activated state and antibody-induced <IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrin<SUP> </SUP>clustering does not result in further stimulation of the coreceptor<SUP> </SUP>activity. Thus, activated <IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0">5<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">1 integrins also mediate parvovirus<SUP> </SUP>B19 entry into primary human erythroid progenitor cells
To investigate the possibility that cytokine responses to acute<SUP> </SUP>parvovirus B19 infection have a bearing on the clinical manifestations<SUP> </SUP>and outcome of infection, we examined B19 virus-infected patients<SUP> </SUP>both at the time of acute infection and again at follow-up for<SUP> </SUP>B19 virus markers, autoantibodies and serum cytokines [IL-1<IMG SRC="/math/beta.gif" ALT="{beta}" BORDER="0">,<SUP> </SUP>IL-2, IL-6, IL-10, tumour necrosis factor (TNF)-<IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"> and IFN


Introduction
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER>
<TR><TH ALIGN=left><FONT SIZE=-1><A HREF="#top">
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Introduction</FONT><BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Material and methods<BR></A>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Results<BR></A>
<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Discussion<BR></A>
<A HREF="#ACK"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">Acknowledgements<BR></A>
<A HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

The majority of the human population worldwide seems to be infected<SUP> </SUP>with the helper virus-dependent parvovirus, adeno-associated<SUP> </SUP>virus (AAV, 6 serotypes, types 2, 3 and 5 infecting humans)<SUP> </SUP>(Erles <I>et al</I>., 1999<A HREF="#ERLES-ETAL-1999"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>). Infection seems to take place <I>in utero</I>,<SUP> </SUP>in childhood and in young adults, where the virus might be sexually<SUP> </SUP>transmitted (Han <I>et al</I>., 1996<A HREF="#HAN-ETAL-1996"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Burguete <I>et al</I>., 1999<A HREF="#BURGUETE-ETAL-1999"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Rohde<SUP> </SUP><I>et al</I>., 1999<A HREF="#ROHDE-ETAL-1999"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>). Persistent AAV infection has been found in human<SUP> </SUP>female genital tissues at various frequencies (Tobiasch <I>et al</I>.,<SUP> </SUP>1994<A HREF="#TOBIASCH-ETAL-1994"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Han <I>et al</I>., 1996<A HREF="#HAN-ETAL-1996"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Friedman-Einat <I>et al</I>., 1997<A HREF="#FRIEDMAN-EINAT-ETAL-1997"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Walz <I>et<SUP> </SUP>al</I>., 1998<A HREF="#WALZ-ETAL-1998"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Sato <I>et al</I>., 1999<A HREF="#SATO-ETAL-1999"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Odunsi <I>et al</I>., 2000<A HREF="#ODUNSI-ETAL-2000"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Coker <I>et<SUP> </SUP>al</I>., 2001<A HREF="#COKER-ETAL-2001"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>). Although AAV is thought to be non-pathogenic, there<SUP> </SUP>are hints for a role in miscarriage (Tobiasch <I>et al</I>., 1994<A HREF="#TOBIASCH-ETAL-1994"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>).<SUP> </SUP>More recently, we reported on the presence of AAV DNA in the<SUP> </SUP>sperm cell fraction of semen samples from infertile men (Rohde<SUP> </SUP><I>et al</I>., 1999<A HREF="#ROHDE-ETAL-1999"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>). Furthermore, using cell culture and helper virus<SUP> </SUP>super-infection, infectious AAV virions could be isolated from<SUP> </SUP>semen. To further assess a possible role of AAV in disorders<SUP> </SUP>of the male reproductive system, the prevalence of AAV in semen<SUP> </SUP>samples presenting a normal or abnormal semen analysis, and<SUP> </SUP>in testicular biopsies of infertile men with azoospermia, was<SUP> </SUP>analysed. In addition, infection with genital helper viruses<SUP> </SUP>for AAV replication (human papillomavirus [HPV] and cytomegalovirus<SUP> </SUP>[HCMV]) was tested (McPherson <I>et al</I>., 1985<A HREF="#MCPHERSON-ETAL-1985"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>; Walz <I>et al</I>., 1997<A HREF="#WALZ-ETAL-1997"><IMG BORDER=1 WIDTH=8 HEIGHT=7 ALT="Go"
SRC="/icons/fig-down.gif"></A>;<SUP> </SUP>Ogston <I>et al</I>., 2000
In mid-May 1999,&nbsp;the patient presented with symptoms of anemia and was
found to have a hemoglobin of 73&nbsp;g/L (7.3&nbsp;g/dL). He<SUP> </SUP>was
transfused with packed red cells. Due to the microcytic, hypochromic<SUP> </SUP>nature of his anemia, the patient underwent a complete endoscopic<SUP> </SUP>evaluation of his gastrointestinal tract, which failed to reveal<SUP> </SUP>an
obvious bleeding source. He presented 3&nbsp;weeks later with similar<SUP> </SUP>symptoms of anemia and a hemoglobin of 63&nbsp;g/L (6.3g/dL), and he<SUP> </SUP>required another red cell transfusion. The corrected reticulocyte<SUP> </SUP>count
was less than 1%. At this time, a bone marrow aspiration<SUP> </SUP>was
performed, which revealed findings consistent with pure red<SUP> </SUP>cell
aplasia. Also visualized were large pronormoblasts with nuclear<SUP> </SUP>inclusion bodies that were very suggestive of parvovirus infection<SUP> </SUP>(Figure <a href="#F1">1</a>). There was no evidence of
lymphoma by flow cytometry,<SUP> </SUP>and PCR analysis failed to demonstrate the
<I>bcl-2 </I>gene mutation


Case report
</FONT></TH></TR></TABLE>
<TABLE ALIGN=right CELLPADDING=5 BORDER><TR><TH ALIGN=left><FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Top<BR></A>
<A  HREF="#ABS"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Abstract<BR></A>
<A  HREF="#BDY"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/uarrow.gif">Introduction<BR></A>
<IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/dot.gif"><FONT COLOR=464c53>Case report</FONT><BR>
<A  HREF="#BIBL"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 ALT=" "
SRC="/icons/toc/darrow.gif">References<BR></A>
</FONT></TH></TR></TABLE>
&nbsp;<BR>

A 48-yr-old woman, without previous medical history, suffered<SUP> </SUP>from polyarthralgia in 1995 for 4 months. Recurrence of these<SUP> </SUP>complaints, associated with fatigue, an urticarian rash, muscle<SUP> </SUP>pain and weakness, started in December 1996, without pulmonary<SUP> </SUP>or gastrointestinal manifestations or hepatitis. Because of<SUP> </SUP>the persistence of these symptoms, the patient was hospitalized<SUP> </SUP>in February 1997. Joint examination showed painful second and<SUP> </SUP>third metacarpophalangeal joints and feet, without evidence<SUP> </SUP>of swelling. There was significant muscle weakness associated<SUP> </SUP>with a purple rash of the upper eyelids. An electromyographic<SUP> </SUP>study showed a myogenic pattern. The erythrocyte sedimentation<SUP> </SUP>rate was 100 mm but C-reactive protein was normal. Serum creatinine<SUP> </SUP>phosphokinase was 724 IU/l (normal value 30&#150;125) and aldolase<SUP> </SUP>22 IU/l (normal value &lt;7.6). Tests for rheumatoid factor<SUP> </SUP>and antinuclear antibodies were positive [1/7016 (latex assay)<SUP> </SUP>and 1/4096, respectively]. Antibodies SSA, SSB, Sm, RNP, Scl70<SUP> </SUP>and Jo1 were negative. HLA genotype was A2-A4-B45-B50-DR4B1*0406-DR7-DR53-DQ2-DQ4.<SUP> </SUP>An EMG-guided deltoid muscle biopsy was performed 10 weeks after<SUP> </SUP>the onset of symptoms. It showed perivascular lymphocyte and<SUP> </SUP>plasmocyte infiltration with areas of muscular necrosis. A diagnosis<SUP> </SUP>of DM was considered. No family history of neuromuscular and<SUP> </SUP>autoimmune diseases was found. The patient was not exposed to<SUP> </SUP>chemicals or particular drugs before or during the onset of<SUP> </SUP>disease. No recent history of infection, in particular with<SUP> </SUP>parvovirus B19, was found in the family


Since the cause and pathogenesis of DM remain unclear, the contribution<SUP> </SUP>of an infectious agent is also difficult to establish. Many<SUP> </SUP>factors are probably involved, including genetic and hormonal<SUP> </SUP>components. Conversely, many viruses have been studied for their<SUP> </SUP>possible contribution to DM [<A HREF="#R1">1</A>, <A HREF="#R5">5</A>]. Regarding this case, it<SUP> </SUP>is likely that the virus itself was not the cause of muscle<SUP> </SUP>damage, but that an undefined aberrant host immune response<SUP> </SUP>was triggered by the parvovirus, leading to muscle destruction.<SUP> </SUP>The presence of parvovirus B19 DNA in our two muscle biopsies<SUP> </SUP>was established using primers for VP1 and NS1. At a 5-month<SUP> </SUP>interval, the two samples were positive for VP1, which may be<SUP> </SUP>active in the formation of infectious viral progeny. Only the<SUP> </SUP>second sample was positive for NS1. In this context, it is of<SUP> </SUP>interest to note that NS1 has been associated with persistent<SUP> </SUP>infection and may therefore be involved in the pathogenesis<SUP> </SUP>[<A HREF="#R15">15</A>]. Similarly, recent data suggest a link between the apoptotic<SUP> </SUP>pathways activated by the combination of tumour necrosis factor<SUP> </SUP><I><IMG SRC="/math/alpha.gif" ALT="{alpha}" BORDER="0"></I> and NS1 in human erythroid cells [<A HREF="#R16">16


